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Colorectal Cancer (CRC) is the third most common and leading cause of cancer death in
the United States. Although CRC screening can prevent and detect CRC at an early stage, about
35% of Americans are not screened. Despite the recent increase in screening, people with lower
SES and those who live in rural areas have lowest screening. In rural areas, a common obstacle
for screening is the long trips for health services which is associated with advanced CRC.
Moreover, surgery is a substantial part of CRC treatment since stages I-III and some
metastatic CRC (mCRC) patients are treated with surgery. Up to 25% of patients who undergo
surgery get readmitted to the hospital due to several factors which costs $300 million annually.
Prior studies showed some variations in CRC treatment between rural and urban patients.
The purpose of this study was to assess the association between rural-urban status and
CRC screening, stage at diagnosis and the receipt of CRC surgery. There were three specific aims:
1) To assess the impact of rurality on CRC screening, 2) To assess the impact of travel time on the
stage of CRC diagnosis, and 3) To evaluate rural-urban differences in healthcare utilization.
We conducted analyses using data from Blue Cross Blue Shield of Nebraska (BCBSNE)
between 2012 and 2016. For Aim 1, the study population included BCBSNE members aged 50-64
years with average-risk CRC. For Aim2, the study population included BCBSNE members aged 50-

64 years with average-risk CRC. For Aim 3, the study population consisted of CRC patients between
the ages of 19-65 years old who had CRC surgery during the study period.
Claims data were used to ascertain the CRC screening, diagnosis, receipt of surgery and
hospital readmission using ICD and CPT codes. Rural-urban status was based on the Rural-Urban
Commuting Area Codes and travel time between the residence and the provider facility was
calculated using Google Map. For Aim 1, prevalence rates for FOBT and colonoscopy were
calculated and compared using X2-test. Univariate and multivariate logistic regression analyses
were performed to assess the relationship between the independent variables and CRC screening
test. For Aim 2, we used Wilcoxon rank-sum tests for continuous variables and X2-tests for
categorical variables and we adjusted for covariates using logistic regression. For Aim 3,
Readmission and surgery status were estimated using multivariate logistic regression.
There was no significant difference between rural and rural residents in colonoscopy use.
However, after adjustment, rural residents were 47% more likely to use FOBT. Patients who do
not use preventive services were 2.80 more likely to present with mCRC and urban residents were
3.50 times more likely to receive mCRC. The fact that 12% of our population presents with mCRC
suggests some non-compliance with screening guidelines. Therefore, we recommend removing
barriers that prevent rural patients from receiving screening colonoscopy and thus increase early
detection of CRC. Until these obstacles have been lessened, screening with more convenient tests
is encouraged. The use of mailed FOBT test is easy and more accessible.
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CHAPTER 1: INTRODUCTION

Epidemiology of Colorectal Cancer in the US
Burden of Colorectal Cancer
Colorectal cancer (CRC) is a malignant tumor of the large intestine or rectum. It is the third
most common cancer in the US preceded by lung and breast cancers in women and lung and
prostate cancers in men.1 CRC is also the third leading cause of cancer deaths in the US.2 According
to the Surveillance, Epidemiology, and End Results (SEER), in 2017 there will be 135,430 new cases
of CRC and 50,260 deaths from CRC.3 The total annual cost of care for CRC is projected to increase
between 2010 and 2020, from $6.0 billion to $7.2 billion for the diagnosis, from $4.0 billion to
$4.9 billion for the treatment and from $4.3 billion to $5.3 billion for the end-of-life care.4
Overall, the lifetime risk of developing CRC is about 1 in 21 for men and 1 in 23 for
women.5,6 As shown in Figure 1, since 1975, the risk of developing CRC has varied by gender, with
males having consistently higher incidence rates than females, possibly due to higher prevalence
of the risk factors such as physical inactivity and limited consumption of fruits and vegetables.6-9
CRC Incidence
For both males and females, the incidence rate has steadily declined between 1975 and
2013 from 68.45 per 100,000 to 42.90 per 100,000 among males and from 53.66 per 100,000 to
32.42 per 100,000 among females.5 According to Figure 2, the incidence rates declined among all
groups with Whites and Blacks had the largest decline.5 Before 1985, Whites had higher incidence
rates than Blacks, but the trends started to reverse in 1985 when rates for both Whites and Blacks
started declining. This decline was sharpest among Whites—a decrease from 67.2 per 100,000 in
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1985 to 36.0 per 100,000 in 2013, compared with Blacks – from 64.1 per 100,000 to 46.3 per
100,000.10 The decline occurred with a corresponding increase in colonoscopy screening among
the Medicare population.11,12

Figure 1. Trends in Age-Adjusted Incidence Rates for Selected Sites by Gender, United States, 1975
to 20126
CRC Mortality
Mortality data showed overall consistent declining trends for both Blacks and Whites with
a steeper declining curve among Whites.2 Starting in 1988, Whites had declining death rates –
from 25.1 per 100,000 to 14.1 per 100,000, while Blacks showed less decline – from 29.2 per
100,000 to 19.3 per 100,000. The rapid decline in death rates among Whites occurred due to an
increase in early detection and increasing polypectomy rates.2 Other races have had lower
mortality rates including Hispanics and Asian/Pacific Islanders.
As shown in Figure 3, the time trend of death rate has a distinct pattern by gender. The
death rate among males peaked around 1945 with a rate of 36.0 per 100,000 and remained steady
until around 1985 when the rate started to decrease gradually to 17.34 per 100,000 by 2012;
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among females the peak was also around 1940, but afterwards the rate immediately declined
consistently to reach 12.12 per 100,000 by 2012.6 Declines in both incidence and death rates of
CRC have been attributed to the decline in the prevalence of risk factors and the increased
screening.2,6,13 Recently, the sharp decline in the mortality rate of CRC (1990-2012) is due to
increases in colonoscopy screening rates.2,14

Figure 2. Trends in Age-Adjusted Incidence and Death Rates for Colorectal Cancer by Race, United
States, 1975 to 201310
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Figure 3. Trends in Age-Adjusted Death Rates for Selected Sites by Gender, United States, 1930 to
20126
CRC Incidence and Mortality Rates by Age Group
Like most other cancers, incidence and death rates of CRC increase with age. Overall, 90%
of new cases and 94% of deaths occur in individuals 50 years and older;2,15 in fact, the incidence
rate of CRC is more than 15 times higher in adults 50 years and older than those between 20 and
49 years. While the CRC death rate has declined in both older and younger age groups, the decline
was greater for those 65 years and older than those between 50 and 64 years old.15,16 Specifically,
more than 70% of the decline in death is among individuals 65 years and older.2 This pattern might
be partly explained by higher CRC screening rates among individuals 65 years and older.16 In July
2001 the Congress enacted a law to entitle Medicare beneficiaries who are at average risk of
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developing CRC to colonoscopy screening every ten years.11,12 By 2005, 47% of people 65 years
and older had been screened compared to only 33% of those 50-64 years of age.12
CRC Incidence and Mortality Rates by Geographic Location
Incidence and death rates of CRC vary by geographic location.14,17 Overall, the ageadjusted incidence rates are highest in the Midwest and lowest in the Northeast. For instance, the
lowest rate was in District of Columbia while the highest was in Kentucky.17 As shown in Figure 4,
CRC mortality rates are highest in the South and Midwest in both White and Black men and
women.14 In the northeast regions, where mortality rates have decreased, there has been an
increased utilization of CRC screening tests. Other factors that have contributed to such regional
variations include access to screening and treatment facilities, which is also influenced by regional
differences in socioeconomic status.17-19 Therefore, the need for a study that assesses the
distribution of screening utilization while controlling for socioeconomic status is warranted.
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Figure 4. Colorectal Cancer Death Rates by State, 2006-201017

Risk and Protective Factors for Colorectal Cancer
Overview
Factors that increase the risk of CRC are older age (≥65 years old), meat consumption,
alcohol intake, smoking, and obesity, while factors that reduce the risk are consumption of fruit
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and vegetables, physical activity, aspirin intake and consumptions of other nutrients (e.g., fiber
and dairy products).20,21 In this section, these factors are discussed in details.
Average Risk Population
Average risk population is individuals who are at least 50 years old, with no personal
history of CRC or adenomatous polyps, no personal history of inflammatory bowel disease, no
family history of CRC or polyps or a known family history of a hereditary CRC syndrome such as
familial adenomatous polyps or Lynch syndrome.22
Age
The mechanism behind the increasing incidence rate of CRC with age is related to the
aging process.23 In a normal colorectal epithelial cell, hypermethylation (i.e., an addition of methyl
groups) of tumor suppressor genes is associated with increased cell proliferation and
differentiation, a characteristic that precedes the development of cancer. The hyperproliferation
(i.e., increase in cell divisions) accumulates over time and manifests at an older age. Additionally,
as explained below, tumorigenesis involves genetic alterations that take decades to manifest into
CRC which also explains the role of age as a potential CRC risk factor.
In the U.S., the risk of CRC increases with age regardless of gender or race.6 However,
recent incidence rate trends show that the disease is increasing among people younger than 50
years of age and slightly decreasing among those 50 years and older. Of the various types of CRC,
proximal colon cancer, or a tumor located in the right and transverse colon, increases with age
from 26-27% in the youngest age group (younger than 50 years) to 49-56% (80 years and older).2
In addition, people younger than 50 years of age had the lowest annual percentage changes in
incidence rates of proximal colon cancer between 2001 and 2010 (-0.2%) compared to the older
age groups (ages 50-64 years: -2.8% and ages ≥65 years:-2.7%). On the other hand, rectal cancer
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is more common among younger individuals. While only 1 in 5 rectal cancer patients 80 years and
older presents with the disease, 2 in 5 rectal cancer patients younger than 50 years present with
the disease.
Dietary Factors
Increased fruit and vegetable consumption has been associated with lower risk of CRC.20,21
Vegetables contain substances with antioxidant properties such as carotenoids and ascorbate as
well as bioactive compounds such as flavonoids.21 Another component of vegetable is folic acid,
which is also available as a nutritional supplement. Folic acid is a water-soluble vitamin B, which
plays a vital role in the transfer of one-carbon during biosynthesis of purines and thymidylate
during

DNA

synthesis.24

Folate

is

also

an

intracellular

coenzyme

(5,

10-

Methylenetetrahydrofolate) that is needed during the conversion of deoxyuridylate to
thymidylate which is oxidized to 10-formyltetrahydrofolate for purine synthesis. Due to its role in
DNA synthesis and stability, folate reduces DNA damage and protects against CRC
development.20,25
Similarly, calcium intake and dairy food might lower risk of CRC through a reduction in cell
proliferation. Multivitamin supplements, non-steroidal anti-inflammatory drugs, and hormone
replacement therapy contribute to the reduction of CRC as well.21 The anticarcinogenic properties
of these compounds reflect their preventive effect, which has been found in studies such as the
Health Professional Study, the Nurses’ Health Study and the Seventh Adventists Study.26,27
In contrast, increased consumption of red and processed meat is associated with an
increased risk of CRC.20 Heterocyclic amines (HCAs) and polycyclic aromatic hydrocarbons (PAHs)
are chemicals produced when meat is cooked at high temperature or directly over open flame.28
HCAs are produced as a result of the reaction between amino acids, sugars, and creatine at a high
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temperature. PAHs are produced when fat from meat drips into the fire and form flames; these
flames contain PAHs, which remain on the surface of the meat.28 The Nurses’ Health Study found
a 2.5-fold increase in risk among women who consumed meat frequently compared to women
who rarely ate meat. Likewise, the Male Health Professional Study showed that men with 5 or
more servings per week of meat had a statistically significant higher risk of CRC.29
Obesity
A large geographic variation in CRC incidence rates reported in migration studies suggests
the roles of different lifestyle factors such as obesity, which plays a significant role in the etiology
of CRC. Previous studies suggested that obese individuals are up to 60% more likely to develop
CRC compared with normal weight individuals.30 The association is stronger among colon cancer
patients when compared with rectal cancer patients. Additionally, the risk tends to be higher
among obese men compared with obese women.31
Cigarette Smoking, Alcohol Intake, and Other Factors
Tobacco smoking is associated with both an increase in incidence and mortality of CRC.32
Compared to non-smokers, smokers are 2-3 times more likely to develop premalignant
adenoma.33 Likewise, daily alcohol intake is linked to an increase of about 40-70% in the risk of
CRC occurrence.34,35 Together, alcohol and smoking might act in synergy to increase CRC risk.
Moreover, insulin and insulin-like growth factors contribute to the regulation of human growth
and development and thus promote cell proliferation and angiogenesis while preventing
apoptosis in the colon. Finally, individuals diagnosed with type-2 diabetes, those who are
physically inactive, and those who are overweight have higher risk of CRC.36
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High-Risk Population
High-risk population is individuals who had a personal history of CRC or adenomatous
polyps, personal history of inflammatory bowel disease, family history of CRC or polyps or a known
family history of a hereditary CRC syndrome such as familial adenomatous polyps or Lynch
syndrome.22
Personal History of Inflammatory Bowel Disease
Individuals with diseases that cause long-term inflammation of the colon are at increased
risk of CRC.37 The two Inflammatory Bowel Diseases (IBDs) associated with the development of
CRC are Crohn’s disease and ulcerative colitis. While Crohn’s disease affects the bowel wall,
ulcerative colitis involves inflammation of the bowel mucosa.38 Regardless of one’s age, people
diagnosed with IBDs, have 4-20 fold the risk of CRC development compared with those without
IBDs.39
Personal History of Adenomatous Polyps
Almost all CRCs develop from precursor benign polyps, primarily adenomatous polyps.40,41
Adenomatous polyps that are large (>1cm), with high-grade dysplasia and with villous features
are more likely, if not removed, to develop into CRC within 5-10 years.42 In the average US
population, the lifetime risk of developing adenomatous polyps is 19%.38 CRC is a largely
preventable disease since colonoscopy with polypectomy is associated with up to 76% reduction
of the occurrence of CRC43 and a 53% decrease in CRC mortality.44
Family History of Colorectal Cancer or Adenomatous Polyps and Inherited Genetic Risk
Approximately one in five individuals diagnosed with CRC have at least one family
member with adenomatous polyps or CRC.38,45 Those with first-degree relatives, who were
diagnosed with adenomatous polyps or CRC, are more likely than those with non-first-degree
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relatives to develop the disease. Both environmental, as well as genetic factors, contribute to the
occurrence of CRC among family members with a history of polyps and CRC. Furthermore, CRC
due to inherited genetic risk occurs in 5-10% of the CRC patients. The two common inherited
conditions are Familial Adenomatous Polyposis (FAP) and Hereditary Nonpolyposis CRC (HNPCC).
Both will be explained in details in the pathogenesis section below.

Pathogenesis of Colorectal Cancer
CRC Pathways and Tumorigenesis
Fearon and Vogelstein were among the first to describe colorectal tumorigenesis, or the
process of cancer formation, by defining the stages of disease development.46 They proposed a
genetic model of colorectal tumorigenesis or the adenoma-carcinoma pathway for the occurrence
of CRC (Figure 5). Fearon and Vogelstein showed four distinctive genetic alterations that are
pertinent to CRC; the mutations of ras gene (i.e., activation of oncogene) and the deletion of
chromosomes 5q, 17p, and 18q (i.e., inactivation of tumor suppressor genes). These alterations
accumulate over time, and the percentage of alterations tends to increase from approximately
25% during early adenomas to 49% in intermediate adenomas. Over 90% of carcinomas have two
or more alterations. Although these stages can occur in any order, Figure 5 illustrates the most
typical order of CRC tumorigenesis as it consistently occurs in populations with different race and
ethnicity, and in various geographic locations.20,46
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Figure 5. Genetic Model Of Colorectal Tumorigenesis46
During the early stage of tumorigenesis, the Adenomatous Polyposis Coli (APC) gene,
which is located in chromosome 5q, undergoes germline or somatic mutation. This loss or
silencing of the APC gene results in the change of the normal epithelium into the
hyperproliferative epithelium. For the development of early adenoma (i.e., adenoma with a size
of ≤ 1cm), an additional clonal expansion is implicated and results in DNA-hypo-methylated
adenomas. Further mutations in the K-ras gene result in an intermediate adenoma (i.e., > 1cm)
but without the foci for carcinoma. Further gene mutation or loss on chromosome 18q or tumor
suppresser gene P53 will subsequently lead to late adenoma (i.e., > 1cm) with the carcinoma foci.
Eventual accumulating loss of the tumor suppressor gene leads to carcinoma and then metastasis.
CRC is a heterogeneous disease, with four distinct molecular pathways that lead to CRC,
as described by Potter et al. (Figure 6).20 The first is the adenoma-carcinoma sequence, where the
APC gene is mutated. The second is the Lynch syndrome pathway, where the DNA mismatch
repair gene is lost either through inherited or acquired mutation or methylation. The third is the
dysplasia-carcinoma sequence, where CRC develops through ulcerative colitis (no APC mutation
or polyp formation). Fourth and final is the hypermethylation silencing of the estrogen receptor
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genes, which is more common in sporadic CRC. These different pathways have an impact on
disease progression, screening, and treatment. The US Preventive Services Task Force (USPSTF)
guidelines suggest that high-risk groups such as those diagnosed with Lynch syndrome or FAP
should be screened at an early age, which typically occurs ten years earlier than the general
population.47,48

Figure 6. Colorectal Cancer Pathways20
CRC tumorigenesis consists of three main stages: initiation, progression, and
transformation (Figure 7).49,50 At the initiation stage, some normal colon stem cells will outgrow
adjacent cells due to various stimuli (genetic or environmental). Because of this increased
abnormal cell growth, normal cells become hyperplastic (i.e., tissue growth due to excessive
proliferation while maintaining the same cell structure as normal cells); with more proliferation,
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hyperplastic cells become dysplastic cells (i.e., a premalignant tissue characterized by an increased
cell number with nuclear abnormalities) (Figure 7). During the progression stage, dysplastic cells
will undergo additional genetic events that will result in the development of abnormal growth in
the lining of the colon; this abnormal yet benign tumor is called a polyp and is considered an early
adenoma. It takes several years during the last stage, the transformation stage before advanced
adenoma develops. If the advanced adenoma or polyp is not removed it will lead to a malignant
tumor.51

Figure 7. The Sequences from Normal to Cancer Tissue52
Classification of CRC
Based on personal and family history, CRC is classified into syndromic and sporadic.
Approximately 15-30% of CRC is syndromic or hereditary and occurs in persons with first- or
second-degree relatives who have had CRC.45,53 The two most common syndromic CRC cancers,
which are associated with increased risk of CRC occurrence, are FAP and HNPCC (i.e., Lynch
Syndrome). On the other hand, sporadic CRC, which accounts for 70-85% of CRC cases, occurs
among average-risk persons with no genetic risk factors. Somatic CRC develops due to somatic
mutations over the course of the lifespan through the exposure to environmental and lifestyle

15

risk factors. The rate of disease progression is higher in syndromic than in sporadic CRC. For
instance, the likelihood of developing adenoma among individuals with a defect in the DNA
mismatch repair gene (DNA MMR), an inherited mutated gene among patients with Lynch
syndrome, is not different from the general population. However, once the adenoma has
developed, progression to carcinoma is faster than the progression among sporadic CRC patients
due to the irreparable damage caused by DNA MMR defect.20

CRC Screening
The Available Screening Tests
CRC screening is recommended for average-risk individuals (i.e., no history of CRC, polyps
or inflammatory bowel disease) starting at age 50.48,54 CRC screening tests include three stoolbased tests, four imaging tests, and two endoscopy tests. The stool tests are gFOBT, FIT and fecal
DNA test. The imaging tests are double-contrast barium enema (DCBE), computed tomographic
colonography (CTC), magnetic resonance colonography (MRC) and capsule endoscopy.47 The
endoscopy tests are flexible sigmoidoscopy (FS) and colonoscopy. The most commonly used tests
in the US are colonoscopy, FS, FIT, and high-sensitivity gFOBT.55,56 The current National
Comprehensive Cancer Network (NCCN) guidelines recommend the following screening methods
and frequency: annual high sensitivity guaiac-based fecal occult blood test (gFOBT) or fecal
immunochemical test (FIT); FS every five years with stool blood tests (FOBT or FIT); and
colonoscopy every ten years.43,48,57
Effectiveness of Screening Tests
CRC screening tests can be classified according to their effectiveness in detecting
adenomatous polyps, and CRC.43 While FS, colonoscopy, DCBE, and CTC can detect both
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adenomatous polyps and cancer, gFOBT, FIT, and stool DNA test with high sensitivity can only
detect cancer. Tests that are effective in detecting both are more invasive, require bowel
preparation, associated with more complications (e.g., perforation and bleeding) and are
costly.43,47
CRC screening can prevent cancer with the use of polypectomy and can detect CRC at an
early stage.43 The National Polyp Study found that polypectomy could decrease up to 76% of CRC
incidence.58 Subsequent studies corroborated such findings but with a lesser reduction in CRC
incidence.59,60 The National Polyp study also estimated a reduction of 53% in CRC deaths due to
polypectomy.44 Many other studies have found decreased mortality with screening.47 Taken
together, evidence suggests a reduction in both incidence and mortality rates with CRC screening.
It should be noted, however, that the effectiveness of screening using colonoscopy varies
between specialties.61-64 Non-gastroenterologists are significantly less likely to detect and remove
polyps compared with gastroenterologists. Specifically, general surgeons are 20% less likely, and
internists are 7% less likely to detect and remove polyps compared with gastroenterologists.61
This study, however, relied on physician’s specialty without considering the training level on
colonoscopy use. Nonetheless, failure to detect polyps, a precursor lesion of CRC, undermines the
main purpose of screening using colonoscopy, which is to prevent CRC through polypectomy.

Diagnosis
Clinical Diagnosis
CRC is diagnosed histologically through biopsy taken during endoscopy.65 Because 2%-4%
of patients present with synchronous tumors, complete colonoscopy or CT colonography must be
performed to detect additional tumors. Other approaches (flexible sigmoidoscopy plus barium
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enema or CT colonography) might be alternative options for patients with contraindication for
colonoscopy (e.g., those with high comorbidities). For rectal cancer, because the treatment is
based on the exact location of the tumor, the use of endoscopic ultrasonography (EUS) is
necessary to for an accurate diagnosis and staging. A meta-analysis of the diagnostic accuracy of
the EUS test shows that EUS is accurate for measuring T staging of rectal cancer.66
CRC Staging
According to the 2016 staging manual of the American Joint Committee on Cancer (AJCC),
the staging for CRC is based on Tumor, Node, and Metastases (TNM) categories.67 T1 tumors
involve the submucosa, T2 tumors involve muscularis propria, T3 tumors penetrate through
muscularis propria, T4a tumors penetrate through the surface of visceral peritoneum, and T4b
tumors invade or are adherent to other organs. The classification of lymph node involvement
includes tumors with one positive lymph node (N1a), 2-3 positive lymph nodes (N1b), 4-6 lymph
nodes (N2a) and ≥7 lymph nodes (N2b). Metastatic tumors include metastases to one organ
(M1a), metastases to multiple distant organs (M1b) and peritoneal carcinomatosis with or
without blood-borne metastases to visceral organs (M1c).

Treatment
Colon Cancer
According to the NCCN guidelines, for non-metastatic colon cancer cases, the primary
treatment depends on tumor resectability and the presence of colon obstruction by a tumor.67
For a resectable non-obstructing tumor, colectomy with en bloc (i.e., cancer adherent to other
organs) removal of regional lymph nodes is indicated. A resectable tumor that is blocking the
colon is treated according to the patient’s condition, which might include a one-stage colectomy
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with en block removal of regional nodes, resection with diversion, or diversion or stent and then
colectomy. However, if the tumor is unresectable, systemic therapy (e.g., chemotherapy or
biologics) is indicated with the objective of shrinking the tumor to make the tumor more operable.
The three primary organs for metastasis for CRC are liver, lung and abdomen/peritoneal
cavity. Tumors metastasized to the liver, the lung, or both are approached similarly. For those
with resectable primary tumor and resectable metastases of liver or lung or both, patients are
treated with staged or simultaneous resection. For patients with unresectable metastases, the
systemic treatment is the only option even if the primary tumor is not obstructed. Among the
most recommended systemic therapy are Folinic Acid-Fluorouracil-Oxaliplatin (FOLFOX) and
Folinic Acid-Fluorouracil-Capecitabine (FOLCape). Finally, patients with peritoneal metastases
have shorter survival compared with those without peritoneal metastases, and the goal of the
treatment of most cases is palliative rather than curative .67
Rectal Cancer
Rectal cancer patients are treated according to the clinical stage at diagnosis.68 Those
diagnosed with early stage rectal cancer are primarily treated with surgical resection, usually done
by local excision.67 However, patients who present with a locally advanced disease are more likely
to receive neoadjuvant (i.e., before surgery) chemoradiotherapy followed by an appropriate
surgical treatment. The primary goal of the chemoradiotherapy is to increase tumor resectability
by downsizing the initial tumor. In contrasts to early-stage tumors, treatment of advanced stage
tumors is through radical excision (i.e., excision of the rectum and mesorectum).
There are several rectal cancer surgeries depending on tumor characteristics such as
location and size. Among the surgical approaches that have been used are transanal excision,
transanal endoscopic microsurgery, transanal minimal invasive surgery, transabdominal
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resection, and sphincter-sparing surgery. In contrast to colon cancer, rectal cancer is usually
treated with neoadjuvant therapy of chemoradiation. For early stages, chemoradiation is for
those with T3-4 tumors that are node negative but where the tumor has penetrated the muscle
wall. In stage-III, neoadjuvant chemoradiation is recommended for all tumors, and adjuvant
chemotherapy is indicated in both stages II and III.

Metastatic Colorectal Cancer
Treatment
Twenty percent of CRC patients are diagnosed with metastatic CRC.2 With the objective
of planning the treatment, clinicians usually investigate whether the tumor is resectable and
whether patients present with symptoms at the time of diagnosis.67 If the tumor is unresectable,
patients are either treated with neoadjuvant therapy with the goal of making the tumor more
operable or are treated with systemic therapy. However, if the tumor is resectable in both primary
and metastatic sites, it is curable. Unfortunately, only 10%-20% of metastatic CRC patients are
curable.67,69
For curable tumors, there are three common approaches for the treatment of mCRC.70,71
First, in the conventional staged approach, the primary tumor is resected first followed by
chemotherapy for 3-6 months then the metastatic tumor is resected in a second surgery. The
second approach, the liver-first approach, was introduced in 2008. This approach is limited to
asymptomatic patients. It is a staged approach where the metastatic tumor is resected first
followed by resection of the primary tumor. In this approach, neoadjuvant and adjuvant therapies
are used as well. The third one is called the synchronous approach (simultaneous approach). In
this approach, both the primary and metastatic tumors are resected during the same procedure.
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For incurable tumors, if patients present with a symptomatic tumor, primary tumor
resection (PTR) is indicated. The current NCCN guidelines recommend PTR among metastatic CRC
patients with symptomatic disease (e.g., obstruction, bleeding).67 However, for asymptomatic
patients, there is no treatment consensus. Proponents of PTR among asymptomatic cases
advocate surgical intervention because of its potential in preventing symptoms of the unresected
primary tumor. However, some argue against doing so because the surgery can result in
unecessary morbidity and mortality.72-74
Effectiveness of Metastatic CRC Treatment
Among asymptomatic patients, two studies used SEER data to investigate utilization of
PTR.72,75 Cook et al. compared the characteristics and survival of metastatic CRC patients who
underwent PTR with those treated with non-PTR between 1988 and 2000, while Hu et al.
investigated the trends of PTR use from 1988 to 2010 when new systemic therapies
(chemotherapeutic and targeted agents) were introduced to the market. Both studies found a
reduction in PTR use over time, with a major decrease starting in 2001 at the time of introduction
of new systemic therapies. During the same period, there were also increased survival rates
among these patients, but it is unclear if this increase was due to higher use of systemic therapies
or because surgeons are reluctant to operate on asymptomatic patients. Authors were not able
to differentiate symptomatic patients form asymptomatic ones. Because the symptomatic status
(symptomatic versus asymptomatic) is not captured in the data, the increased use of PTR might
be due to selection bias. This bias could contribute to the decreased rate of PTR because it is
unknown if the reduction was due to a decrease in PTR among asymptomatic patients or due to
an increase in systemic therapy.
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An additional study by Xu et al.76 using SEER data tried to circumvent the limitation of the
previous two studies. They used the improved methodology of instrumental variable analysis to
account for unmeasured confounding by linking Health Service Area (HSA) to the county where
PTR took place. The authors reported better survival among the PTR group. They also looked at
the impact of place of residence and found consistent improved overall and cancer-specific
survival in the PTR group among patients in both metropolitan and non-metropolitan counties.
Moreover, when Shapiro et al. investigated the same period using SEER data, they found gender,
geographic region, insurance status, tumor location, tumor grade and Carcinoembryonic Antigen
(CEA) level to be independent predictors of PTR. For instance, insured patients were 35% more
likely to undergo PTR compared with uninsured patients.
A more recent review study74 investigated the differences in patient outcomes among
metastatic patients who were treated with PTR followed by chemotherapy versus those with only
primary chemotherapy. Overall, authors found better survival with PTR, although the two
approaches were comparable. Specifically, among patients with primary chemotherapy, 3%-40%
presented with complications of the unresectable primary tumor with onsets that varied between
3-12 months. The most common complications included obstruction, perforation, hemorrhage,
and pain. On the other hand, complications among patients who underwent PTR were wound
infection, anastomotic leaks, urinary tract infection and ileus which required subsequent surgical
intervention in 3%-11% of cases. In addition, postoperative mortality ranges from 2%-5% with a
single study reporting an estimate of 29%. Lastly, factors that are more likely to predict overall
survival among reviewed studies were the extent of hepatic involvement, Eastern Cooperative
Oncology Group (ECOG) performance status ≥2, as well as metastatic dissemination to at least
two distant sites compared to disease confined to one organ
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Sphincter-Sparing Surgery
Surgery Types and Effectiveness
The two primary rectal cancer surgeries are Sphincter-Sparing Surgery (SSS) with
intestinal continuity (also known as low anterior resection or LAR) and sphincter scarifying surgery
with permanent colostomy (also known as abdominoperineal resection or APR).77 Not all rectal
cancer patients are candidates for SSS. In general, the lower the tumor (i.e., the lower third of the
rectum), the more difficult it is to resect while maintaining safe margins and therefore the less
likely that SSS in indicated. Nonetheless, the ultimate decision is individualized. With a better
definition of the clear safe margin for resection, the advancement in surgical technique and the
development of staplers, patients with tumors at the lower third can be treated without
sacrificing the sphincter.78,79
Both SSS (LAR) and APR aim at reducing the local recurrence by ensuring tumor-free
margins in the resected specimen. The most significant predictor of increased local recurrence
and reduced survival is the tumor circumferential margin that is defined as the shortest distance
between the mesorectal fascia and rectal tumor. Using histological samples, studies that
compared LAR and APR showed higher positive margin from APR compared to LAR (SSS).80 Given
the importance of sphincter-sparing, while maintaining bowel continuity, it is essential that
patients receive SSS if indicated. Maintaining bowel continuity via SSS has a positive impact on
patient's quality of life.81-83 However, not all patients who are candidates for SSS receive the
surgery depending on tumor, patient and surgeon’s factors.
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Current Knowledge about Colorectal Cancer in the Rural Health Literature
Colorectal Cancer Screening by Geographic Location
While CRC screening rates increased between 2000 and 2008, the increase in the
prevalence of CRC screening among people with lower SES and those who live in rural areas have
been relatively small.84,85 A study showed that rural residents are more likely to perceive that early
detection of CRC is helpful compared with their urban counterparts; however, rural residents are
less likely to receive screening for CRC.55 Using the national Behavioral Risk Factor Surveillance
System (BRFSS) data, Cole et al. assessed CRC screening uptake by geographic location between
1998 to 2005.86 They found that the more rural the place of residence was, the less likely an
individual would get screened. The findings were also corroborated by other studies that used
state-level data.87,88 Additionally, as shown in Figure 8 below, the northeast and some of the
northern regions have the highest rates of CRC screening while the Midwest regions have the
lowest rates.
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Figure 8. Colorectal Cancer Screening (%), in Adults 50 Years and Older, BRFSS 20142
Note: The estimates do not distinguish between examinations for screening and diagnosis.
Screening tests included a fecal occult blood test within the past year or sigmoidoscopy within the
past five years or colonoscopy within the past 10 years.
Travel Time and Stage at Colorectal Cancer Diagnosis
According to the National Household Travel Survey (NHTS), 41% of trips in the US traveled
by rural residents for medical or dental services were longer than 30 minutes while only 25% of
trips traveled by urban residents were longer than 30 minutes.89 Traveling is especially
burdensome for cancer screening, with distance to a screening facility as a significant barrier for
rural patients.88,90-98 This barrier is exacerbated in rural areas where primary care provider density
is low, in particular among the younger adults and people with a lower SES.99 Rural populations
overall are more likely to have unstaged cancers, and if staged disease, it tends to present as
advanced CRC.100
Rural-Urban Status and Colorectal Cancer Care and Outcomes
Surgery is a significant part of CRC treatment since stages I-III and some metastatic
patients are treated through surgery.67 Post-surgery, about 25% of patients who are operated on
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need to get readmitted to the hospital due to factors that are not fully understood.101 Excessive
readmissions following CRC surgery are estimated to cost $300 million annually.102 To contain
these unnecessary costs, the Affordable Care Act includes the provision called the Hospital
Readmission Reduction Program that penalizes hospitals for readmission after surgery.101,103 In
2015, the penalty was 3% reduction in payments for all Medicare admissions during a given
year.104
Suspected factors that contribute to excess readmission can be classified into surgical and
non-surgical. Surgery-related factors consist of preoperative (e.g., surgical approach, procedureurgency, comorbidities, obesity, the severity of illness, and indication), perioperative (e.g.,
operating time and stoma creation and immunosuppression use) and postoperative factors (e.g..
length of stay, complications, non-home discharge, blood transfusion, postoperative steroids).
Non-surgical factors are geographic location, age, gender, race, SES and hospital’s patient
volume.101,102
Several studies have been conducted in the northern and southern part of the US. A multiinstitution study conducted in northern Minnesota, northwest Wisconsin, and the western
portion of Michigan's Upper Peninsula, showed variations in CRC treatment between rural and
urban patients and in general indicated that rural patients are at a disadvantage.105 Another study
from the state of Georgia found no differences in surgical receipts by geographic location.106
However, several studies lacked information about travel time to cancer care, hospital case
volume, SES, patient’s comorbidities and complications.

26

Research Gaps
Previous research on CRC shows that screening decreases incidence and mortality rates
by detecting polyps or tumors at an early stage. Additionally, prior studies found that longer travel
distance to screening facilities to be associated with late stage of diagnosis and delayed or no
surgical treatment. Previous research was limited to self-reported surveys or focused on older
adults (e.g., Medicare beneficiaries). Our study was designed to evaluate CRC screening uptake
among a younger cohort of a privately insured population in a rural state; no previous work
studied the characteristics of the younger CRC patients among the BCBSNE population. The
younger working-age population included in this study are more likely than older population to
have a busy schedule and less motivated to travel to colonoscopy facility to get screened and
therefore more likely to be diagnosed with metastatic CRC. Therefore, this younger population is
an ideal population.
Additionally, no prior studies assessed the CRC surgery use and outcome among this
population. Specifically, none of the previous studies assessed the association between rurality
and 30-day hospital readmission among CRC patients who are privately-insured in a rural state.
Only one study assessed 30-day hospital readmission using privately insured data but was not
focused on CRC patients and, unlike our study, was not examining the impact of rurality on
hospital readmission.
Moreover, the association between rurality and the receipt of mCRC is not well
characterized. For instance, four published studies evaluated the surgery uptake among patient
with mCRC by geography. However, none of the studies assessed the impact of rurality. Instead,
the studies either reported the geographic location of the SEER registry where cases have arisen
(e.g., Northeast, South, etc.) or measured rurality at the county level. Further, none of these
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studies assessed such relationship among the privately insured population. Although previous
research found that in urban areas the odds of undergoing SSS is 1.4 times the odds of surgery in
rural areas, it is not clear if such relationship sustains in a privately insured population who reside
in a rural state.
Furthermore, prior research shows that the majority of SSS were conducted in urban
areas even after adjusting for hospital surgery volume.107,108 This suggests that other reasons
could elucidate the differences between rural and urban population. For instance, higher income
level and the availability of private insurance were associated with higher SSS uptake. It is unclear,
however, if patient’s rurality status would have an impact on the receipt of SSS among the
privately insured population in a rural state. To fill the gaps in the literature, this study had the
following aims and related hypotheses:

Specific Aims
Aim1: To assess the impact of rural residence on CRC screening among 50-64 years old in
a privately insured population.
H1a: Colonoscopy rate is lower in the rural population compared to the urban population.
H1b: FOBT screening rate is higher in the rural population compared to the urban
population.
H2: The urban population has higher PCP visits than the rural population.
H3: Patients with a higher number of PCP visits are more likely to receive CRC screening.
Aim2: To assess the impact of travel time on the stage of CRC at diagnosis among 50-64
years old in a privately insured population.
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H1: Shorter travel time to a colonoscopy facility is associated with a non-metastatic
diagnosis of CRC.
Aim3: To evaluate rural-urban differences in healthcare utilization among CRC patients.
H1: Urban CRC patients who undergo surgery are more likely to have lower readmission
and emergency department visits.
H2: Among patients with metastatic CRC, the proportion who undergo surgery is higher
among the urban population compared with the rural population.
H3: Among rectal cancer patients, the proportion who undergo sphincter-preserving
surgery is higher among the urban population compared with the rural population.

Scope of the Study
Our study is a retrospective cohort study conducted among privately insured adults
residing in Nebraska. This unique population was rarely included in previous CRC studies. The
study is limited to individuals who are 50-64 years old. It is also limited to the period from January
2012 to June 2016. The Institutional Review Board at the University of Nebraska Medical Center
approved the study.

Summary
CRC is the third most common cancer in the US and the third leading cause of cancer
deaths. Although CRC can be prevented or detected at early stages when the treatment results in
high survival rates, a large proportion of individuals are not screened. Specifically, the prevalence
of CRC screening among the rural population and those with lower SES have been less than the
urban population. Among the factors that contributed to lower screening is the distance to the
screening or treatment facilities and this is especially burdensome for the rural patients. Some
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previous studies found that longer travel distance to screening facilities to be associated with late
stage of diagnosis and delayed or no surgical treatment. Additionally, hospital readmission rate
has been shown to be higher among low volume centers which exist primarily in the rural areas.
The study is significant because it is designed to characterize this privately-insured population for
the first time. It is also designed to uncover differences between the rural and the urban
populations in the receipt of CRC screening, the impact of travel time on stage at diagnosis, the
differences in hospital readmission and the receipt of mCRC and SSS among a privately insured
population. In addition to directing future research questions, our findings will have clinical and
public health implications. For instance, if the rural population is less likely to receive indicated
CRC surgery, this might reflect unawareness or disagreement with existing treatment guidelines.
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CHAPTER 2: REVIEW OF THE LITERATURE

Definition and Characteristics of the Rural Population
There are 60 million adults in the US (20% of the US population) living in rural areas.
109,110

Unlike urban communities, rural communities have lower population density, higher non-

working population such as elderly and children, more unemployed or underemployed who are
less likely to be insured.109 Prior research showed that rural population and those with lower
socioeconomic status were less likely to undergo screening, less likely to receive treatment and
at an increased risk of death following CRC diagnosis.85-88,106,111-113
The most widely used definitions of rural and urban populations are established by three
government agencies: The U.S. Census Bureau, the Office of Management and Budget, and the
Economic Research Service of the U.S. Department of Agriculture (USDA) (Table 1).114 The U.S.
Census Bureau relies on total population or population density within a census tract to designate
an area into rural or urban.109,115 There are three classes of areas: An Urbanized Area (UA), an
Urban Cluster (UC) and rural. UA has a population density of 50,000 or more people. The
characteristic of the UA is that it has a core (at least one contiguous census block groups) with a
total land area fewer than two square miles, might contain adjacent territory with at least 500
people per square mile and include a population of at minimum 50,000 people. UC is similar to
UA, but it contains a population less than 50,000 and at least 2,500 people. Any other territory,
population, and housing units located outside the UA and UC areas are considered rural areas.
Unlike the U.S. Census Bureau definition, the office of Management and Budget classifies
counties as metropolitan and nonmetropolitan areas.109,115 Metropolitan areas are core counties
with at least one urbanized area and outlying counties with economic ties to the core county as
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measured by work commute. The outlying counties are considered part of the metropolitan area
if 25% of workers commute to the urbanized area or if at least 25% of employment in the county
consists of workers coming from the urbanized area. Furthermore, the nonmetropolitan counties
are located outside the metropolitan areas and are divided into micropolitan (i.e., any nonmetro
county with a cluster of the urban area more than or equals 10,000 people) and noncore counties.
The USDA has two definitions that are measured at the county level: The Rural-Urban
Continuum Code and the Urban Influence Code.116 The Rural-Urban continuum code classifies
metropolitan counties by the population size of their metropolitan area and nonmetropolitan
counties by the extent of urbanization and proximity to a metropolitan area. Counties are grouped
based on their classification by the Office of Management and Budget (metro and nonmetro) then
subdivided into three metropolitan and six nonmetropolitan classes. Unlike the Rural-Urban
Continuum Code, the Urban Influence Code subdivides the metropolitan area into two
metropolitan groups based on their size. It also subdivides the nonmetropolitan area into ten
nonmetropolitan groups based on their proximity to the metropolitan area, and the
nonmetropolitan-noncore counties into seven groups based on their proximity to metropolitan
or micropolitan areas and if they have their town of more than 2,500 people.
The Rural-Urban Commuting Areas (RUCAs) was developed by University of Washington
with help from the Economic Research Service of the USDA.117 This classification uses the U.S.
Census Bureau’s UA and UC definitions supplemented with information on work commute. The
classification assigns metropolitan, micropolitan, small town and rural commuting areas with
numbers between 1 and 10. These numbers are subdivided into 21 secondary codes based on
commuting flows. Although the original RUCA classification was based on census tract, it uses the
ZIP code as its geographic unit.
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Table 1: Characteristics and Classifications of the Rural-Urban Areas114-116
Classification

Geographic
Unit Used

U.S. Census
Bureau: Urban and
Rural Areas

Census Tract

Pros
•

•

Census is the
smallest and most
accurate
geographic unit.
Reduces the
problem of underbounding or
overabounding
that is associated
with county-based
classifications.

U.S. Office of
Management and
Budget (OMB):
Metropolitan and
Nonmetropolitan
areas

County

•

County boundaries
represent political
jurisdictions and
considered stable
over time.

Economic Research
Service, USDA: The
Urban Influence
Code

County

•

Because it
differentiates
counties with
several small
towns from those
with one or two
large towns for
grouping
nonmetropolitan
counties, it is
better than RUCA
for suggesting a
level of locally
available services.
Proximity to
metropolitan areas
indicates the
degree of
economic
integration with

Cons
•

•
•

•

•

Definition based
on census can
be hard to
implement
because such
small
geographic unit
is not commonly
used by payers.
No stable across
census years.
County size
differ across the
U.S., and larger
counties contain
both rural and
urban areas
(over- and
underbounding)
County size
differs across
the U.S., and
larger counties
contain both
rural and urban
areas.
Does not
differentiate
metropolitan
counties as well
as does RUCA.
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metropolitan
counties.
Economic Research
Service, USDA: The
Rural-Urban
Continuum Code

County

RUCA

Census
tract/ZIP code
approximation

County boundaries
represent political
jurisdictions and
considered stable over
time.
•

•

ZIP code areas are
easy to implement
with programs that
are dependent on
provider or
beneficiary
address.
Structuring of the
codes allows for
multiple levels of
generalizationfrom 2 (ruralurban) to 33.

County size differs
across the U.S., and
larger counties contain
both rural and urban
areas.
•

•

ZIP codes are
unstable and
can change from
year to year.
No stable across
census years.

No matter what definition one uses, the chosen definition will somehow over- or underrepresent urban or rural areas. The definition that dichotomizes areas (metropolitan and
nonmetropolitan or rural and urban) will ignore any gradations in nonmetropolitan areas. For
instance, the use of OMB definition will ignore proximity to metropolitan areas and thus
underestimate the level of locally available services. However, the use of dichotomy is easier
especially if the urban reflects the urbanest areas and the rural reflects the most rural areas.110
According to Hart and colleagues,109 there are three points that researchers should
consider when embarking on a project: the purpose of the study, the availability of data and the
suitability and availability of definition. The primary purpose of our study is to measure travel time
between members and providers. Because current study is not an interventional study (e.g.,
allocating resources or programs to areas that are not part of large urban or rural areas), using
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RUCA as a dichotomy is appropriate. Regarding data availability, we have access to ZIP code
provided by BCBSNE, which is more suitable for RUCA definition. The use of this definition is also
consistent with previous studies, which make results comparable.86,87,118

Roles of Primary Care Providers in Colorectal Cancer Screening
The Institute of Medicine (IOM) defines primary care as “the provision of integrated,
accessible health care services by clinicians who are accountable for addressing a large majority
of personal health care needs, developing a sustained partnership with patients, and practicing in
the context of family and community.”119 This definition emphasizes the important attributes of
primary care such as the accessibility to health services, the sustained relationship between the
healthcare provider and the patient and the integrated care to provide a referral to a specialist
when needed. Primary care practice ensures the availability of a usual source of care, which is a
well-established factor associated with an increased uptake of CRC screening.120-125
Primary care providers (PCPs) include general practitioners or family medicine, internists
and general pediatricians.125 A PCP is the patient's first contact with the healthcare system, and
the preventive services are often initiated through primary care. In case of CRC prevention and
control, the roles of a PCP include discussion and recommendation regarding screening,
performing non-invasive screening (e.g., FOBT), and referring patients to specialists (e.g.,
gastroenterologists, general surgeons or colorectal surgeons) who can perform an endoscopic
screening test.43
Previous research demonstrates favorable CRC outcomes associated with PCP visits. For
example, improved outcomes such as a lower incidence of late-stage CRC and a higher survival
are proportional to the supply of PCPs.19,126-128 For each 10% increase in the supply of PCPs
measured by the number of PCPs per 100,000 people, the odds of late stage diagnosis of CRC is
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reduced by 5%.128 In particular, non-metropolitan areas with high level of PCPs supply is
associated with less late-stage CRC.19 In contrast, each 10% increase in the supply of specialists
such as gastroenterologists, general surgeons or colorectal surgeons is associated with 5%
increase in late-stage CRC diagnosis. This could be because of the nature of the relationship
between PCPs and patients, which tends to be longer and covers patients’ overall health, as
opposed to the limited contact between specialists and patients.129

Figure 9. Primary Care Physician Supply versus Demand, by State, 2025128

Roles of Geography in Colorectal Cancer Screening Use
There are many factors associated with the use of CRC screening including race,
socioeconomic status, health insurance coverage, availability of a usual source of care,
communication with provider, level of knowledge about CRC screening, rural residence and
geographic access to screening facilities.85,130-132 An analysis of Behavioral Risk Factor Surveillance
System (BRFSS) data indicated that rural residents are 17% less likely to be up-to-date on overall
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CRC screening compared with urban residents.86 Moreover, compared to the urban and the rural
residents, the remote rural (often termed as “frontier”) residents are the least likely to receive
CRC screening.86 Limited use of CRC screening among the rural and the frontier community can
be explained by the lack of access to screening facilities, the differences in individuals’ preference
for the screening tests (e.g., individuals tend to prefer non-invasive tests such as FOBT) and the
differences in provider’s recommendations (e.g., providers recommend colonoscopy, which is
recommended once every 10 years, for individuals who are less likely to comply with the annual
tests).
A recent study in Nebraska found similar disparities in CRC screening.113 Hughes and his
colleagues used the Health Belief Model to elucidate factors that contribute to a lower CRC
screening, especially in rural Nebraska. The study found significant differences between the rural
and the urban populations regarding their beliefs about CRC screening. For example, rural
respondents perceived that they are less able to prevent themselves from getting CRC compared
with the urban respondents. Also, there were significant differences concerning access to care,
with rural residents tend to be less likely to identify a regular source of care. Having a usual source
of care is a well-established reason for increased screening uptake.85 Interestingly, 35% of the
rural residents reported that CRC screening cost too much while only 18% of the urban residents
reported that the cost was too high. This view was held even though the majority of survey
respondents were insured.
One possible reason that rural residents are less likely to undergo CRC screening is the
long distances they need to travel to the nearest colonoscopy facility as well as the lack of public
transportation.87,88,113 On average, rural patients travel 30 minutes longer for medical or dental
care compared with their urban counterparts.89 An analysis of the Utah BRFSS data shows that
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among individuals at high risk of CRC (defined as those with a history of CRC, polyps or
inflammatory bowel disease) individuals who traveled less than 10 minutes was significantly more
likely to receive colonoscopy compared to those who traveled 20 minutes or longer. It should be
noted, however, that the study did not find a significant association between the median travel
time to the nearest colonoscopy facility and CRC screening use.88
Long-distance travel may be especially burdensome for CRC screening. Endoscopic
screenings such as colonoscopy come with some logistical challenges such as the need for taking
time off from work and the need for somebody to accompany the patient to the procedure.
Although screening colonoscopy usually takes half an hour, as the patient needs to be sedated,
the procedure requires the patient to take at least a day off from work or other usual activities.
Also, because of sedation, the patient needs somebody to drive him or her back home after the
procedure. Additionally, the unpleasant experience of bowel preparation before the procedure
may be problematic for patients who live in the rural areas and need to travel long distance.

Impact of Travel Time on Stage at Colorectal Cancer Diagnosis
As mentioned earlier, an analysis of national BRFSS data and a survey study conducted in
Nebraska suggest that rural residents are less likely to use CRC screening compared to urban
residents and that longer travel time to a colonoscopy facility may be associated with less
likelihood of colonoscopy screening.86,87,113 Furthermore, the literature suggests that rural
residents are more likely to be diagnosed with late-stage CRC compared to urban residents.
However, because of lack of research, the relationship between the travel time and the stage at
diagnosis is not very well understood. To our knowledge, there are only two published populationbased studies that examined the stage at diagnosis.118,133
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Charlton and colleagues used the Iowa SEER Cancer Registry that is linked with the
Medicare claims database to assess both the impact of rural-urban status as well as travel time to
colonoscopy facility on the stage of CRC diagnosis.118 In this Medicare sample, 69% were
diagnosed with late-stage CRC. There was no significant association between rural-urban status
or travel time and stage at diagnosis. Authors speculated that this insignificant finding might be
due to the high accessibility to healthcare services in the state of Iowa since there is at least one
hospital in each county. They also explained that travel time might become less of an issue when
the PCP refers the patient to a gastroenterologist whom the patient is familiar with. Another
possible explanation of the insignificant findings is that those at retirement age might not consider
travel time as a barrier to CRC screening.
The second study was conducted by Massarweh and colleagues using the National Cancer
Data Base (NCDB).133 The authors examined factors associated with metastatic colon cancer
diagnosis. In this study, where half of the patients were younger than 69 years old, authors found
that 50% of their population were diagnosed with late-stage CRC. In the multivariate analysis, the
authors reported a dose-response relationship between age and likelihood of metastatic colon
cancer diagnosis where those younger than 60 years had the lowest odds of metastatic colon
cancer diagnosis. They also showed that men were more likely to be diagnosed with metastatic
CRC compared with women and those who were underinsured or with Medicare or Medicaid
insurance were more likely to be diagnosed with metastatic CRC compared to those who were
privately insured. Additionally, unlike the study from Iowa mentioned above, Massarweh et al.
found a significant association between rural-urban status as well as travel distance and diagnosis
of metastatic colon cancer. Those who lived in urban areas and those who lived in rural areas
were 4% and 8% more likely to be diagnosed with metastatic colon cancer, respectively, compared
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to those who live in metropolitan areas. Additionally, compared to those who traveled a short
distance (<12.5 miles), those who traveled an intermediate distance (12.5-49.9 miles) and those
who traveled a long distance (≥50 miles) were 18% less likely to be diagnosed with metastatic
colon cancer.

Rural-Urban Differences in Receipt of Colorectal Cancer Surgery among
Patients with Metastatic Colorectal Cancer
Twenty percent of CRC patients are diagnosed with metastatic CRC. While 10%-20% of
metastatic CRC cases are curable2,67,69 CRC surgery among resectable metastatic CRC patients is a
complex procedure and requires a multidisciplinary team to ensure safe and effective operation.
Several prior studies found a positive association between the hospital surgery volume and clinical
outcomes, which led many to advocate centralization of care (i.e., concentrate complex surgeries
at high-volume hospitals). Toward that end and to ensure high-quality procedures, there has been
an increase in the centralization of complex cancer surgery including ones for CRC.134 However,
despite the benefit of centralization, travel barriers undermine the beneficial effect of
centralization especially among the rural population,134-136 regardless of one’s insurance
status.137,138
There is a paucity of research that investigates the association between rural-urban status
and surgery uptake among patients diagnosed with metastatic CRC. Four published studies
assessed geographic location as a covariate in multivariable analyses.72,73,76,139 These studies found
that while patients in the northeast are less likely to undergo PTR those who reside in the south
are more likely to receive PTR. Further, 71.8% of those who live in the metro counties and 58.3%
of those who live in the nonmetro counties have received PTR. However, these studies focused
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on incurable metastatic CRC where the focus of the papers was on the PTR as opposed to
synchronous or staged-resection of all metastatic tumors for curative purpose.

Regional Variations in the CRC surgeries
The provision of CRC surgeries varies by the geographic location and the availability of
surgical centers with adequate surgery volume.134,135,140 Depending on the procedure type, the
volume of surgery can widely vary by region which leads to the different distance traveled by
patients to the treatment center. For instance, the distance traveled for esophageal cancer
procedure ranges between 4.4 and 30.7 miles, for pancreatic cancer procedure between 3.0 and
18.0 miles, for colon procedure between 1.9 and 9.3 miles and rectum procedure between 2.2
and 9.9 miles. While the distance traveled to low-volume hospitals is usually shorter, the distance
traveled to the high-volume hospitals is longer. For hospitals with very high volume, the distance
traveled for esophageal cancer procedure ranges between 13.4 and 57.5 miles, for pancreatic
cancer procedure between 9.6 and 43.3 miles, for colon procedure between 2.9 and 11.9 and
rectum procedure between 4.8 and 24.5 miles. The differences in the provision of surgery
according to the procedures’ volume resulted in regional variations depending on procedure type.
The Regional Variation model classifies factors associated with regional variations into
clinical and environmental factors.141 Examples of clinical factors include the physician’s decision
to refer the patient to a surgeon or the surgeon’s belief about the indication for the surgery.
Furthermore, examples of the environmental factors are technology diffusion, the supply of
surgeons and financial incentives. Clinical factors reflect differences in disease incidence rates
such that the higher the incidence of the disease the higher the observed volume for a given
operation.134,135 Further, regional differences are a reflection of variations in the use of cancer
detection methods such as screening, which subsequently leads to more or fewer surgeries.13 For
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instance, an ecological study of prostate cancer found that Seattle, which had a higher screening
rate than Connecticut, had a higher rate of prostatectomy use than Connecticut.142
Additionally, regional variations in CRC surgery is a result of differences in the availability
of diagnostic testing. Since colonoscopy is the primary diagnostic test for CRC, both the availability
of colonoscopy as well as the accessibility to a facility where colonoscopy is provided are essential
to ensure timely tumor detection and, if indicated, surgical resection. Timely detection of tumors
varies according to ones’ travel distance,133 disadvantaging rural residents.89
Physician’s referral pattern is another reason that contributes to regional variations in
CRC surgery. Depending on the type of surgery, physicians have different opinions on whether to
operate and on the need to refer the patient to a high-volume hospital where the likelihood of a
better outcome is higher.141 For example, variation in volume is measured using Systematic
Component of Variation (SCV), where high SCV scores indicate large geographic variations and
low SCV scores reflect low variations. Whereas prostatectomy has a very high score of 13.5,
colectomy has low SCV score of 3.5 which reflects the consensus in clinical evidence that surgery
is the treatment of choice for colon cancer patients.141 In other words, patient's preferences are
less likely to influence treatment in colectomy but contribute significantly to prostatectomy
(where the patient has to balance the psychological benefits of tumor removal and survival after
surgery versus the risk of sexual dysfunction and permanent urinary incontinence from surgery).
Unlike prostatectomy where there are significant variations between low and high-volume areas,
colectomy is less likely to vary,143 and therefore referral is less likely to impact surgical uptake.
The supply of surgeons also contributes to the regional variations in CRC surgery. Since
1970, the supply of general surgeons has been steadily decreasing mainly because of the
increased surgical sub-specialization, the aging of surgeons and the lack of training.144 For
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example, during the past 25 years there was a 26% reduction in the number of general
surgeons.145 Regions with the least supply is the rural areas where 56% of the rural counties have
no general surgeons.146 Moreover, general surgeons lack advanced training, for example in
laparoscopic and endoscopic techniques, which are predominant in rural hospitals.145

Factors Associated with Sphincter-Sparing Surgery (SSS)
There has been an increase utilization of SSS between the years 1988 (35.4%) and 2006
(60.5%).107,108 Many factors determine who receive the SSS including patient, surgeon or hospital
factors. In general, studies found that those who are male, of older age, Blacks, with Medicaid
insurance or those who live in a lower-income ZIP code were less likely to receive the surgery.
Additionally, high-volume hospitals located in urban areas were associated with a higher use of
SSS compared to hospitals located in rural areas.
Age is a significant predictor of SSS use where almost all previous studies found that the
use of surgery significantly decreases with age.107,108,147 Among those who are younger than 60
years of age, the likelihood of receiving the surgery is 21% higher compared with those who are
60 years or older [OR: 1.21 (95% CI: 1.13, 1.29)].107,108 The differences in SSS use by age is due to
the less aggressive treatment with aging (including any surgical intervention) and the lower
likelihood of survival among elderly who underwent surgery.147 For instance, after adjustment for
sex, race and tumor characteristics such as grade and stage, increased age is significantly
associated with an increased likelihood of dying from rectal cancer. The magnitude of the
likelihood of dying is higher among those 70 years and older [RR: 1.31 (95% CI: 1.25, 1.36)]
compared with patients 69 years and younger [RR: 1.10 (95% CI: 1.05, 1.15)].147
There are also racial disparities in the receipt of SSS, which have been reported in previous
studies.107,148 After adjusting for stage and patients’ characteristics, a study using the SEER
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database found that Blacks were 42% more likely to receive sphincter sacrificing procedure.
Additionally, Ricciardi and colleagues noted a decline in SSS use among Blacks; the authors
speculated that the decline might be due to geographic segregations where Blacks are less likely
to see a physician who is sufficiently competent to operate.149
While only 11% of patients who live in the rural areas receive SSS, the majority of patients
who underwent SSS live in urban areas.108 In urban hospitals, where the volume of SSS is higher
than rural hospitals, the odds of undergoing SSS is 1.4 times the odds of receiving surgery in rural
hospitals [OR: 1.38 (95% CI: 1.26, 1.52)], even after adjusting for variations in SSS volumes
between the rural and the urban hospitals, which indicates that other factors might explain
variations between the rural and the urban areas.108 Other speculated factors include higher
income level as well as the availability of private insurance, both of which are associated with the
increased uptake of SSS.107 However, It is unknown if patients in rural areas will differ from those
who live in urban areas in the rate of SSS uptake especially among a privately insured population.

Factors Associated with Colorectal Cancer Surgical Outcomes
Compared with the urban residents, the rural population tends to be older, with a lower
income and with a lower level of education.101,150,151 These characteristics have been found to be
associated with lower CRC surgery rates or poor outcomes.101,102,139,151 In addition to these
differences, the rural population has more geographic barriers to cancer care especially
sophisticated surgical therapy.152,153 This lower level of access to surgical care contributes to the
worse surgical outcomes that have been experienced by the rural residents such as higher
mortality, surgery-related complications and hospital readmission.150,154 For instance, the rural
population is more likely to undergo cancer surgery as a result of a non-elective hospital
admission.150
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Many factors contribute to the increase in hospital readmission after colorectal surgery,
including older age, male gender, Black race, lower income, lower education, being unmarried,
lack of insurance, higher deprivation score, and lower SES. In general, previous studies of CRC
surgeries found that the older the patients, the more likely that they were readmitted after the
index surgery.155-159 Compared to the individuals who were 50 to 64 years of age, those who were
65 and older were more likely to readmit. The odds of readmission increase proportionally with
age.159,160 Those who were more likely to get readmitted within 30 days after CRC surgery tended
to have increased odds of one-year mortality compared to those who were not, and this pattern
in mortality increased with age.160,161 Moreover, mortality among older age groups (>80 years)
compared with younger age group (<50 years) was higher in the rural hospitals [OR: 5.74 (95% CI:
3.45, 9.54)] compared to the urban hospitals [OR: 4.32 (95% CI: 3.81, 4.90)].
In addition to the association between age and hospital readmission, gender and race
were found to predict hospital readmission. Most studies found that male patients were more
likely to be readmitted compared to female.102,155,159,161,162 For instance, Greenblatt et al. using
SEER-Medicare database found that males were 20% more likely to be readmitted to the hospital
within 30 days of CRC surgery, and 21% more likely to die within one year.161 One of the
hypothesized reasons is that males tend to have longer hospital stay compared with females.155
Additionally, Blacks were 17% more likely to be readmitted compared to Whites.155
Moreover, clinical factors such as higher comorbidities, the use of immunosuppressant or
steroids and obesity are associated with a higher likelihood of readmission.156,163-167 There are
consistent findings between the association of comorbidity and readmission, a relationship which
increases with the increased level of comorbidities. For instance, one study that used claims
database reported a 13% increase in the hospital readmission rate as the severity of illness level
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increased from 0 to 3, and a 29% increases in readmission as the severity of illness level increased
from 0 to 4. Likewise, Schneider and colleagues found that those with Charlson Comorbidity Index
(CCI) of 3 or higher were 27% more likely to be readmitted compared to those with a comorbidity
score lower than 3.159
Although readmission rates vary between 9%-25%, these variations reflect differences in
perioperative factors. Specifically, readmission is higher among patients diagnosed with IBD,
those admitted urgently, those with longer operation time, patients with complications and those
discharged to nursing homes.

Summary
In this chapter, we defined the rural population, identified different classification systems
for the rural and the urban populations including the pros and cons of each system and explained
the characteristics of the rural population. We found that using RUCA system is more appropriate
for the current study. We also defined PCPs and identified their role in the CRC screening process
and the benefits (e.g., early detection of CRC or referral to specialists) associated with having a
usual source of care. We then elucidated factors associated with CRC screening rates according
to geography and stated that previous research found that rural residents are 17% less likely to
be up to date in CRC screening. Some of the potential reasons for such lower screening rate is that
rural patients are less likely to identify a usual source of care and more likely to travel long
distances to receive care. Further, we evaluated the current literature on CRC stage at diagnosis
between the rural and the urban populations and especially the effect of travel time. Although
many studies have found that the rural population is less likely to get screened and more likely to
get diagnosed at a later stage, the evidence is controversial about the impact of travel time on
the stage of CRC diagnosis. These inconsistent findings are due to different study populations and
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different sources of data. Moreover, there is a paucity of research about CRC treatment
differences between the rural and the urban populations who are privately insured, especially the
surgery use among those diagnosed with metastatic CRC and the SSS among rectal cancer
patients.
This study is designed to fill these gaps in the literature. Unlike previous studies, our study
characterizes the CRC screening among the privately insured population who live in a rural state.
It also sheds light on the impact of travel time on CRC stage at diagnosis using working-age
population, which we believe has never been studied. This population is unique because unlike
other population (e.g., Medicare), the younger working population has busy schedules and are
therefore less inclined to travel to colonoscopy facility to get screened and thus are more likely
to present with metastatic CRC.
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CHAPTER 3: RESEARCH METHODS

Overview
The current study is a retrospective cohort study using claims data from the state of
Nebraska. The primary data used in this study were BlueCross BlueShield of Nebraska (BCBSNE),
supplemented by information from the Rural-Urban Commuting Area Codes Data (RUCA), Health
Professions Tracking Service (HPTS) and Google Map. The outcome variables were CRC screening
use, stage at diagnosis of CRC, hospital readmission and emergency department visit following
CRC surgery, CRC surgery use among patients diagnosed with metastatic CRC, and sphinctersparing surgery utilization among rectal cancer patients. The exposure variables included ruralurban residence, travel time, and travel distance. The main analyses were X2-tests, Wald test, and
multivariate logistic regressions.

Data Sources
BlueCross BlueShield of Nebraska
BCBSNE is the largest private health insurance company in Nebraska serving over 700,000
people.168 The claims file, which contains 72,160,334 visits, includes services that occurred
between January 1, 2012, and June 30, 2016, and were paid through September 15, 2016. These
services consisted of verified claims from inpatient, professional and outpatient facilities. The data
were limited to the providers and members who lived in Nebraska during the time the service was
provided.
The member file, which contains 920,227 visits, includes all members who were active
between January 1, 2012, and June 30, 2016. The file also contains member’s demographic
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information such as age, gender, member- and provider-5-digit ZIP codes. BCBSNE also captures
members’ beginning and ending date of coverage. Diagnosis and procedural codes for the
relevant inpatient, outpatient, and professional claims are all available as well.
To assess sample representativeness, the proportion of the BCBS members residing in
each regional health department district was compared to that of the Nebraska population
(Appendix D). The proportions were similar except for Dakota County Health Department (0.35%
for BCBS vs. 1.15% for state population) and for West Central District Health Department (0.23%
for BCBS vs. 2.16% for state population).
The Rural-Urban Commuting Area Codes Data
RUCA is a publicly available data published by the University of Washington.169 It is a
classification scheme that is based on census tract and uses the standard Bureau of Census
Urbanized Area and Urban Cluster definition in combination with work commuting information
to characterize all of the census tracts regarding their rural and urban status and their
relationship.
RUCA codes are based on the same concepts utilized by the Office of Management and
Budget (OMB) to define county-level metropolitan and micropolitan areas. The RUCA codes used
the same criteria by OMB by categorizing the U.S. census tracts using measures of population
density, urbanization, and daily commuting.116 The latest RUCA codes are based on the 2010
decennial census and the 2006-2010 American Community Survey.
There are ten primary and 21 secondary codes in RUCA. The primary codes consist of
whole numbers (1-10) that represent metropolitan, micropolitan, small town, and rural
commuting areas based on size and direction of largest commuting flows. The secondary codes
subdivide the ten codes based on secondary commuting flows. Therefore, the classification
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satisfies various needs by allowing users to choose their preferred definitions. For the current
study, we used “Categorization C” to dichotomize the area of residence into rural and urban. We
used this categorization because other categorization would break the sample into subgroups that
are too small.
Google Maps Data
Commercial websites such as Google offer accurate driving directions between places.
Open-source programming language (i.e., developed by the referenced authors) that is available
on SAS was used to make repeated calls to Google to obtain travel time information for any
number of locations.170 Subsequently, the program was tested by the same authors using a
nationally representative sample that covers 66,000 locations in the fifty states, the District of
Columbia and Puerto Rico.171 The authors suggest that the SAS code could change to reflect the
occasional changes in Google web site structure. For example, if Google map changes its URL, the
same change must be reflected in the FILENAME statement in SAS (Please see below for
FILENAME method).
In this study, we utilized publicly available Google Maps to calculate travel time as well as
travel distance. We calculated travel time by measuring time in minutes between the geographic
centroid of each member ZIP code of residence and the provider ZIP code at the time of service.
Travel time calculations were made via repeated calls to the Google Maps Web page using SAS
FILENAME URL method in SAS.171 The method has a high correlation with straight-line distance
(r2=0.96) but with superior travel time estimate. When both members and providers had the same
ZIP code (i.e., artificial zero bias), we conducted a sensitivity analysis to assess the impact of small
variations of travel time (1-, 10-, and 20-minutes) on the metastatic stage at diagnosis.172 There
were no changes in the proportion of metastatic CRC with the changes in travel time.
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Health Professions Tracking Service (HPTS)
The HPTS is Nebraska’s healthcare workforce monitoring systems since 1995.173 It collects
information about health care providers practicing in Nebraska. The collected information
includes profession, license type, primary specialty, training, expertise, languages spoken fluently,
retirement plans, practice setting and arrangements for all practice site locations, the ZIP code
and county of practice location. The list of professionals is updated periodically to reflect active
practitioners in Nebraska.
We used HPTS data to measure access to PCP. The measure is based on the provider-topopulation ratio and calculated by dividing the total number of actively practicing PCPs (i.e.,
medical or osteopathic physician who specializes in general practice, internal medicine or family
practice) in each ZIP code by the total population of each ZIP code.110

Study Samples
There were two samples for Aim 1 (Sample-1 and Sample-2; Figures 10 and 11 below).
The objective of using Sample-1 was to assess the annual use of FOBT or colonoscopy. The
eligibility criteria for Sample-1 were BCBSNE members aged 50-64 years old during the year and
with average-risk CRC. The cut-off age of 50 was used because this age is considered the averagerisk age for the development of CRC according to the USPSTF guideline.48 We excluded members
who were 65 years and older because of their supplemental Medicare insurance. That is, these
members have additional coverage through Medicare, and therefore some of their procedures
are not captured in BCBSNE. We also excluded members with high risk of development of CRC
during each year.
As shown in Figure 10, we first identified the 765,868 members in BCBSNE who have any
membership coverage between January 1st, 2012 and June 30th, 2016. We excluded members who
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have duplicate enrollment records, overlap in the coverage periods or gaps in enrollment more
than 31 days.174 These exclusions, though not part of eligibility criteria, were necessary to prepare
data for final analysis. Among the 688,299 members with no lapse in coverage of more than 31
days, we excluded 546,703 individuals who were outside of the age group of interest. Next, we
excluded 36,448 high-risk members defined as members who had a personal history of CRC or
adenomatous polyps or a personal history of inflammatory bowel disease. We were unable to
exclude members with a family history of CRC or polyps or a known family history of a hereditary
CRC syndrome such as familial adenomatous polyps or Lynch syndrome because these members
are not captured in the data. A total of 105,148 members met the eligibility criteria for Aim 1
Sample-1. Finally, we looked at every single year and identified members who have coverage for
the entire year. Some members have coverage for more than one year.
Moreover, the objective of using Sample-2 was to assess the association between ruralurban status and the CRC screening use (Figure 11). We limited our cohort to members who were
continuously-enrolled during the 2013-2015 period (319,245). We did so to ensure the
temporality between the covariates and the outcome. That is, we want to ensure that the CRC
screening tests occur after PCP visits. We further limited the sample to the age groups 50-64 years
old and members with average risk CRC (78,891). Finally, we excluded members with no records
(the only available variables for these members was their IDs). A total of 58,774 members met the
eligibility criteria for Aim 1 Sample-2.
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Figure 10. Aim 1 Sample-1 Selection Flow Chart
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Figure 11. Aim 1 Sample-2 Selection Flow Chart
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For Aim 2, the study sample consisted of members aged 50-64 years old with no history
of cancer (Figure 12). Out of the 688,299 members, we excluded a total of 546,703 members who
were younger than 50 years because they are not recommended for screening. We excluded
members who were older than 65 years of age because the BCBSNE data likely did not contain
claims for all their health services that may have been covered under Medicare. We also excluded
140,771 people with no diagnosis of CRC. Further, we excluded 149 members with no inpatient
claims or fewer than two outpatient claims for CRC because they did not meet our CRC diagnosis
definition. We also limited our sample to those with 6-month continuous enrollment before CRC
diagnosis and those with no prior cancers. We chose the six months cut-off time to ensure that
the identified cases are incident and not prevalent cases.175
We conducted sensitivity analysis, that is guided by publications from Setoguchi and
colleagues,175 Song and colleagues,176 Paramore and colleagues,177 and Rao and colleagues.178
These definitions have high agreement with cases reported in the cancer registry in the date of
the first diagnosis. All definitions reported by the authors resulted in high specificity and good
sensitivity for identifying incident cases. Given that CRC is a rare outcome and in order to improve
statistical efficiency, we chose the definition that resulted in high sensitivity. Accordingly, we
assumed that those who met the definition of at least one inpatient or at least two outpatient
claims of CRC and who have no CRC cancer within six months prior to first CRC diagnosis to be
diagnosed with CRC (see Appendix C).
For the travel time analysis, we limited our analysis to members who had colonoscopy
claims during the four months prior to CRC diagnosis. We conducted a sensitivity analysis to assess
the impact of different continuous enrollment periods (4, 6, 9, 12, 18 and 24 months) on
percentages of colonoscopy use and on whether the identified cases were incident not prevalent

55

cases. A total of 204 members met the eligibility criteria and used in the calculation of travel time
(Figure 12).
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Figure 12. Aim 2 Eligibility Criteria
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For Aim 3, Hypotheses 1-3, the study sample consisted of CRC patients between the ages
of 19-65 years old (Figures 13-15). Of the 688,299 members, we excluded the following: 255,934
who were younger than 19 years or 65 years or older, and 431,290 with no CRC diagnosis. For
Hypothesis 1, the following additional exclusion criteria were applied: no inpatient claims or fewer
than two outpatient claims or those who were not continuously enrolled for six months before
CRC diagnosis (n=147), no surgery claims (n=284), and no admission or discharge dates (n=72). A
total of 315 members met the eligibility criteria (Figure 13).
For Hypothesis 2, the following additional criteria were applied: no inpatient claims or
fewer than two outpatient claims or those who were not continuously enrolled for 6 months prior
to CRC diagnosis (n=147), no metastatic stage at diagnosis for CRC (n=487), no inpatient claim or
fewer than two outpatient claims for mCRC (n=23), and diagnosed with other primary cancers
(n=92). A total of 69 members met the eligibility criteria (Figure 14).
For Hypothesis 3, the following additional criteria were applied: no diagnosis of rectal
cancer (n=431,863), diagnosed with anal cancer (n=121), no inpatient claims or fewer than two
outpatient claims (n=136) and no rectal cancer surgery (n=155). A total of 90 members met the
eligibility criteria (Figure 15).
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Figure 13. Aim 3-Hypothesis 1 Eligibility Criteria
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Figure 14. Aim 3-Hypothesis 2 Eligibility Criteria
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Figure 15. Aim 3-Hypothesis 3 Eligibility Criteria
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Key Variables and Measures
Table 1 summarizes select key variables and measures. In the following, assumptions and
definitions for the key variables and measures are described.
Coverage Dates, Service Dates and Age at Diagnosis
To identify the coverage period, variables called “beginning date of coverage” and
“ending date of coverage” were identified from the BCBSNE enrollment files. These variables were
used during the data preparation step when we removed duplicate records and corrected the
coverage periods (e.g., by removing overlap coverage). For beginning and ending dates of service,
the first and last dates of service by a recognized medical practitioner during the study period
(1/1/12-6/30/16) were used to identify services related to the research questions (e.g., CRC
diagnosis). Age at diagnosis was identified using the age when the first CRC diagnosis was reported
within the six months continuous enrollment provided.
CRC Risk, Diagnosis and Staging
Claims data were used to identify individuals who had ICD codes for the malignant
neoplasm of colon or rectum (excluding anal cancer). For the specific codes used, see Appendix
B. Individuals were considered to be diagnosed with CRC if they had at least one inpatient claim
or at least two outpatient claims for CRC diagnosis during the study period (2012-2016). ICD codes
are based on codes used in a similar study by several authors118,133,175 (Appendix B3). Note that
given that the BCBSNE did not provide CRC diagnosis variable, we had to make assumptions to
develop an operational definition of CRC diagnosis. These assumptions were guided by
publications from Setoguchi and colleagues,175 Song and colleagues,176 Paramore and
colleagues,177 and Rao and colleagues.178 For instance, we applied the definitions suggested by
Setoguchi and colleagues to define incident CRC in administrative data. These definitions have
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high agreement with cases reported in cancer registry in the date of the first diagnosis. All
definitions reported by the authors resulted in high specificity (99.62%-98.51%) and good
sensitivity (67.25%-88.02%) for identifying incident cases. Given that CRC is a rare outcome and
in order to improve statistical efficiency, we chose the definition that resulted in a high sensitivity.
Accordingly, we assumed that those who met the definition of at least one inpatient or at least
two outpatient claims of CRC to be diagnosed with CRC. Based on a study by Gupta et al. who
used claims data to study CRC, high-risk groups was operationally defined as those who have
previous CRC diagnosis, polyps diagnosis or inflammatory bowel disease.179
Given that BCBSNE does not have a variable to identify stage at diagnosis, we reviewed
the literature and consulted with the surgeon about measuring CRC stage at diagnosis. Several
publications have used secondary malignant CRC as a surrogate for metastatic CRC176,177 and
metastatic breast cancer.178 Thus, we assumed that patients who were diagnosed with secondary
metastatic neoplasm, according to Appendix B4, would have been diagnosed with metastatic CRC.
In this study, the CRC staging was dichotomized into metastases versus non-metastatic CRC.
Metastasis was defined as the occurrence of at least one inpatient claim or at least two outpatient
claims for metastatic CRC codes (Appendix C) within 30 days before CRC diagnosis or any time
after CRC diagnosis. These codes have also been used elsewhere.177
CRC Screening
In order to define the purpose of colonoscopy (i.e., Screening versus Diagnostic or
Surveillance), we identified the pertinent ICD and CPT codes. Members were classified as having
a diagnostic colonoscopy if they received claims indicating CRC symptoms such as blood in stool,
rectal bleeding or abdominal pain four months prior to colonoscopy (see Appendix X for specific
codes used). To be classified as having surveillance colonoscopy, members should not have claims
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associated with potential CRC symptoms but should have diagnoses indicating a history of a
condition that merits more frequent CRC surveillance such as polyps or IBD. Members who did
not meet the diagnostic or surveillance criteria above were classified as having a screening
colonoscopy (see Appendix B1, B2, and B5 for specific codes used).
We assessed members who received colonoscopy within four months prior- or two weeks
post-diagnosis of CRC to determine if the purpose of colonoscopy was screening, surveillance or
diagnostic (Appendix C6). We conducted sensitivity analysis for periods between three and six
months prior- and between two weeks and six months post-diagnosis. But this sensitivity analysis
resulted in fewer additional colposcopies identified. For instance, restricting to six months of
continuous enrollment before diagnosis resulted in 210 cases, four months resulted in 204 cases
and three months resulted in 200 cases. Likewise, restricting continuous enrollment for a postdiagnosis period of 14 days resulted in 22 cases, 30 days to 25 cases, 60 or 90 days to 31 cases,
120 days to 35 cases and 180 days to 44 cases. We decided to choose four months prior- or two
weeks post-diagnosis of CRC because of the fewer cases identified by extending the time.
CRC Surgery and Readmission
Receipt of CRC surgery was defined as the endoscopic removal of polyps (polypectomy),
local excision, resection of the primary tumor with or without stoma creation among patients with
six months continuous enrollment before CRC diagnosis and six months continuous enrollment
after CRC diagnosis. The one year of continuous enrollment was chosen to ensure that we are not
missing surgeries conducted after systemic therapy according to guidelines (i.e., surgery after
neoadjuvant therapy).67 For the codes used to identify surgeries, see Appendix B7 and B8. These
codes were used after consultation with the surgeon and after meeting with the trained coder.
Additionally, these codes were guided by previous publications.101,102,155,161,180 After applying these
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codes, we found that the rate of CRC surgery is lower than what has been reported in the
literature.101 To fully understand the lower rates of CRC surgery, we conducted a sensitivity
analysis. Please refer to Appendix C for the detailed explanation and results of the sensitivity
analysis.
Finally, the 30-day readmission was defined as the number of patients who were
discharged from hospital and readmitted within 30 days divided by the number of all people who
were discharged. The same definition has been used in a previous publication.181 Operationally,
we used the inpatient records and the two variables created by BCBSNE (admission date and
discharge date) to measure hospital readmission. For the codes used to determine the
readmission, see Appendix B.
Classification of Rural-Urban Status
According to RUCA developer,117 a total of 33 codes can be used to categorize geographic
population. A researcher can collapse these codes into categories that fit his or her research
objectives. For instance, one can choose categories from the table below. Consistent with the
relevant literature, we used Categorization ‘C.’ Since the current study is limited to a sample of
Nebraska residents, we used RUCA Nebraska file.
Measurement of Travel Time to Screening Facility
For the measurement of travel distance and travel time, we used Google Maps as well as
BSBSNE’s provided member’s 5- digit ZIP codes and providers’ 5- digit ZIP codes. Many previous
studies defined distance as the straight-line distance between locations using coordinates or
latitude and longitude. Although the straight-line distance is useful,171 a greater precision can be
achieved using actual road distance when the driving distance is estimated using Google Maps.
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Using the centroid of ZIP code, we calculated the travel time between members and
providers. Accordingly, travel time is defined as the time in minutes between the ZIP codes’
centroid for participants and the ZIP codes’ centroid for providers. There are three main steps for
the calculation of travel distance: 1) identification of distances between a single ZIP code and all
ZIP codes in Nebraska,170 2) combining all calculated distances, and 3) merging distance for the
study sample.
To operationalize travel time, we used the date of the first claim of index colonoscopy to
identify both participants as well as provider addresses. We measured travel time as a continuous
variable and reported the mean and median. When both members and providers have the same
ZIP code, we conducted a sensitivity analysis to assess the impact of small variations of travel time
(1-, 10-, and 20-minutes) on the metastatic stage at diagnosis.
PCP Access and Preventive Service Use
The PCP access was defined as the provider-to-population ratios which highlight gaps in
service availability and delivery.110 It was calculated by dividing the total number of actively
practicing PCPs in each ZIP code by the total population of each ZIP code.
Preventive service use was defined as any health services such as checkups or counseling
to prevent illness or to detect illness at an early stage when treatment is more viable.182 For the
codes used for to identify preventive services, see Appendix B6. These codes have been used in
previous study.183
Primary Care Physician Visits
Primary care physician visits were measured using the number of visit in a calendar year
to a general practitioner, an internist or family practitioner. For Sample-1 of Aim 1, we looked at
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the number of PCP visits during a calendar year. For Sample-2 of Aim 1, we looked at the number
of visits during a two-year period (2013-2014).
Enhanced Charlson Comorbidity Index
Enhanced Charlson Comorbidity Index was developed by Charlson et al. to determine the
burden of disease and case mix.184 Researchers use the index to account for comorbidities in the
regression models. To apply the index to administrative data, other authors modified the
comorbidity index and validated its use.185,186 In 2011, Quan et al. updated the index that was
validated for use in administrative data by adjusting the weights of comorbidities.187

Table 2. Description of select key variable and measures
Variable / Measure
Data Source and Operational Definition
Beginning date of coverage BCBS enrollment file. The first date of BCBSNE coverage.
Ending date of coverage
BCBS enrollment file. The last date of BCBSNE coverage.
Beginning date of service
BCBS enrollment file. The first date of service by a recognized medical
practitioner during the data period 1/1/12-6/30/16. The calendar
year of service derived from date of service.
Ending date of service
BCBS enrollment file. The last date of service by a recognized medical
practitioner during the data period 1/1/12-6/30/16. The calendar
year of service derived from the end date of service.
Age at diagnosis
BCBS enrollment file. Member’s age at the time of CRC diagnosis
Receipt of FOBT
BCBS claims file. Having at least one paid claim for FOBT conducted
during the specified calendar year.
Receipt of screening
BCBS claims file. Having at least one paid claim for non-diagnostic and
colonoscopy
non-surveillance colonoscopy conducted during the calendar year.
Receipt of diagnostic
BCBS claims file. Having at least one paid claim for diagnostic
colonoscopy
colonoscopy (i.e., symptoms such as rectal bleeding) conducted during
the calendar year.
Receipt of surveillance
BCBS claims file. Having at least one paid claim for surveillance
colonoscopy
colonoscopy (i.e., among high-risk individuals with a history of CRC,
polyps or IBD) conducted during the calendar year.
High-risk individuals
BCBS claims file. Having a history of CRC, polyps or IBD.
CRC diagnosis
BCBS claims file. Having at least one inpatient or at least two
outpatient claims of CRC diagnosis during the specified continuous
enrollment.
Metastatic stage of CRC
BCBS claims file. Having at least one inpatient or at least two
outpatient claims of metastatic CRC diagnosis within 30 days before
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Receipt of CRC surgery
ER visit
30-day readmission

Rural-urban status of
member’s residence

Travel time to receive
health care
PCP access
PCP visits

Preventive service use

Enhanced Charlson
comorbidity index

CRC diagnosis or any time after CRC diagnosis during the specified
continuous enrollment.
BSBS claims file. Having at least one claim for CRC surgery during
specified continuous enrollment with BCBSNE.
Emergency department visit within 30 days after CRC surgery.
The number of patients who were discharged from hospital and
readmitted within 30 days divided by the number of all people who
were discharged.
BCBS enrollment file. Based on RUCA classification system, individuals
who lived within the ZIP codes that were designated as a rural area by
RUCA were classified as rural residents, and the remaining were
classified as urban residents.
BCBS denominator and claims files. A straight-line travel time
between the geographic centroid of member ZIP code and the
provider ZIP code at the time of service calculated by Google Map.
2016 HPTS data and 2010 US Census data. The number of actively
practicing PCPs per population in a given zip code.
Primary care physician visits are computed using the number of visit
in a calendar year to a general practitioner, an internist or family
practitioner. For Sample-2 of Aim 1, we looked at the number of visits
during a two years period (2013-2014).
Preventive services are any health services such as checkups or
counseling to prevent illness or to detect illness at an early stage
when treatment is more viable.
A method developed by Charlson et al. and is used to determine
comorbidities or the burden of disease and case mix. Quan et al.
updated the index that is used in administrative data by adjusting the
weights for comorbidities. For Aim 1, we included cancer diagnosis as
part of the measurements of CCI, however; we excluded cancer
diagnosis from the calculation in Aim 3 where all study populations
were diagnosed with CRC.

Missing Data
For Aim 1, there were six observations with missing value for the rural-urban status. For
Aim 2, the only missing variable was “access to primary care physician” (26% missing). We did not
use access to PCP in our analyses. This variable was created using the HPTS data because it is not
available in the BCBSNE data. To circumvent the problem of missing data, we imputed the value
of the missing variable. Because there was an association between other covariates and stage at
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diagnosis, we assumed that “access to primary care physician” is Missing At Random (MAR).
Therefore, multiple imputations using the SAS procedure PROC MI was used. The imputation
consisted of three phases: the imputation phase where we ran a total of 10 imputations; the
analysis phase where logistic regression was used to calculate parameter estimates and odds
ratios; and the pooling phase where the parameter estimates from analysis phases were pooled.
Finally, for Aim 3, there were no missing variables.

Statistical Analyses
We used SAS statistical software version 9.4 (SAS Institute Inc. Cary, NC) to conduct all
analyses. All tests were 2-tailed with α level of 0.05.
Aim 1
The first aim was to assess the impact of rural residence on CRC screening. The first part
of the analysis was to estimate the annual prevalence rates for FOBT and colonoscopy. The
numerator was the number of members with at least one paid claim for the specified screening
test during the specific year. The denominator was the number of members eligible for screening
during the specific year. To compare the rates between urban and rural members, we used X2test. The same test was used to assess the CRC screening use across years as displayed in Figure1.
The second part of the analysis was to assess the association between rural-urban status
and FOBT or colonoscopy use. We estimated the unadjusted odds ratios using univariate logistic
regression. The variables used in the univariate models are age, gender, rural-urban status, PCP
visit in 2013-2014 and CCI. Predictor variables with p-value <0.25 were included in the
multivariate model. We assessed if the association between rural-urban status and the use of
FOBT was modified by assessing the interaction. We found that there were interactions between
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rural-urban status and age, gender and PCP visits. Likewise, there was an interaction between
rural-urban status and age when we assessed the colonoscopy use. We reported the stratified
results by each of the effect modifiers.
Aim 2
We used Wilcoxon rank-sum tests for continuous variables and X2-tests for categorical
variables. We also used univariate analysis to compare metastatic versus non-metastatic CRC
diagnosis using univariate logistic regression. In the univariate analysis, we made comparisons by
age, gender, rural-urban status, use of colonoscopy within four months prior to CRC diagnosis and
travel time. Wald tests were used to assess predictors’ significance. We checked interaction
between travel time and age, gender, rural-urban status, use of colonoscopy within four months
prior to CRC diagnosis and there was no interaction.
We used the fractional polynomial method (PROC LOESS) to examine any non-linear
relationship between the log odds of metastatic diagnosis and continuous variables. We inspected
the curves of the predictors against the dichotomous response and used the likelihood ratio test
for improvement in fit against the assumed linear relationship. Lastly, we conducted a
multivariate logistic regression analysis to assess the relationship between travel time and
metastatic CRC diagnosis adjusting for all variables. Univariate logistic regression analyses were
conducted to assess the association between the predictor variables (age, gender, rural-urban
status, use of preventive services, colonoscopy type, and PCP access) and the metastatic CRC.
Predictor variables with p-value <0.25 were included in the multivariate logistic model.
Multivariate logistic regression was built to adjust for the confounding variables using the stepwise method. There was no interaction between travel-time and predictors. We used PROC
LOGISTIC in SAS statistical software.
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Aim 3
We used descriptive analysis to compare the demographic and clinical characteristics
between the rural and the urban populations. For the significance tests, we used X2-test for
categorical variables and t-test for continuous variables. Hospital readmission was defined as rehospitalization within 30 days of the index hospitalization. Patients with any hospitalization after
the index surgery were identified using inpatient CRC claims. These patients were then classified
according to their time of inpatient visits after the index surgery into hospitalization within 30
days versus more than 30 days. For the univariate analysis, we used logistic regression model to
compare the readmitted patients versus the non-readmitted, and patients who received surgery
from those who did not receive the surgery among all variables; Wald tests were the test of
significance. We also estimated the unadjusted odds ratios using univariate logistic regression
models for the rural residence among those readmitted versus none and those received surgery
versus no surgery. Readmission and surgery status were estimated using multivariate logistic
regression.
Univariate analyses were performed between hospital readmission and clinical and
demographic variables. Logistic regression was conducted to assess the association between
rural-urban status and hospital readmission after adjustment for the following independent
variables: surgery approach, the presence of intestinal obstruction or perforation and CCI. These
independent variables were based on previous knowledge of the association between rural-urban
status and readmission or were with p-value <0.25. The variables include age, gender, travel-time,
LOS, tumor location, site of surgery and stoma creation. There were no interactions between
rural-urban status and independent variables.
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Receipt of surgery among metastatic CRC patients was calculated by measuring the
proportion of CRC patients who were in the rural and the urban population and comparing them
for the receipt of surgery. Receipt of rectal surgery is measured by calculating the proportion of
rectal cancer patients who are in the rural and urban areas and comparing them for the receipt
of surgery. For Hypothesis 2 (the relationship between rural-urban status and the use of surgery
among patient diagnosed with metastatic CRC), univariate analyses were conducted to assess the
relationship between the predictor variables and the use of surgery among patients diagnosed
with metastatic CRC. These variables are age, gender, rural-urban status, CCI, travel-time, primary
tumor site, site of metastasis, number of metastatic sites and access to PCP services. Predictor
variables with p-value <0.25 were included in the multivariate model. Multivariate logistic
regressions were built to adjust for the confounding variables using the step-wise method. We
also assessed the interaction between rural-urban status and all predictors and found no
interaction. For Hypothesis 3 (the relationship between rural-urban status and the use of surgery
among patient diagnosed with rectal cancer), univariate analyses were assessed between ruralurban status and the use of SSS in patients diagnosed with rectal cancer.
Sample Size Calculation
Because some of the analyses were underpowered, a post hoc sample size calculation
was conducted (Table 3). The travel time sample size calculation was based on findings from the
current study: the median travel time of 19 minutes, and those who live closer to the facility to
be less likely to be diagnosed with metastatic CRC (15%). The estimated sample size was
calculated using the PROC POWER in SAS. It was found that for a comparison of two independent
binomial proportions using Pearson's X2-test statistic with X2 approximation with a two-sided
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significance level of 0.05, a sample size of 175 per group has an approximate power of 0.79 when
the proportions are 0.15 and 0.27.
Table 3: Power Analysis
Power analysis for varying proportions of subjects who live >19 minutes from
colonoscopy facility, assuming 0.15 metastatic CRC in subjects who live ≤19 minutes,
α=0.05
Power
Proportion of metastatic CRC in Sample size per group
subjects live >19 minutes of
colonoscopy facility
0.23
0.20
173
0.31

0.21

176

0.40

0.22

179

0.48

0.23

176

0.56

0.24

173

0.65

0.25

176

0.72

0.26

174

0.80

0.27

175

0.84

0.28

173

Summary
The current study is a retrospective cohort study of a privately insured population from
Nebraska. The overall study population comprised of members who met the eligibility criteria as
described in Figures 10-15 between the years of 2012 and 2016. The main exposures were ruralurban status and travel time. The main outcomes were screening use, stage at CRC diagnosis,
hospital readmission and emergency department visits, surgery use among patients diagnosed
with metastatic CRC and sphincter-sparing surgery use among patients diagnosed with rectal
cancer. The statistical analyses used in this study were logistic regression, and all analyses were
conducted using SAS.
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CHAPTER 4: RESEARCH FINDINGS

Aim 1: The Prevalence of Colorectal Cancer Screening by Rural and Urban
Status in Nebraska
Members Eligible for Colorectal Cancer Screening by Demographic Characteristics
As shown in Figure 10 (Aim 1 Study Sample Selection Chart), a total of 105,148 individuals
met the eligibility criteria for this aim: aged 50-64 years, active members of BCBSNE during the
study period (2012-2016), and are of average risk of developing CRC. Table 4 compares the
characteristics of rural and urban members. Despite the statistically significant differences
between the rural and urban populations, the two populations share similar characteristics. For
instance, the majority of the two populations visit the PCP (82% and 83%).
Table 4: BCBSNE Members Eligible for Colorectal Cancer Screening by Rural/Urban Residence
(N=105,148).
Rural
Urban
P-value
Characteristics
(n=52,469)
(n=52,673)
Age
50-54
18365 (35.0)
18977 (36.0)
0.002
55-59
17702 (34.0)
17476 (33.0)
60-64
16402 (31.0)
16220 (31.0)
Gender
Female
27847 (53.0)
29172 (55.0)
<.0001
Male
24622 (47.0)
23501 (45.0)
PCPs visits
Yes
42870 (82.0)
43497 (83.0)
0.0002
No
9599 (18.0)
9176 (17.0)
CCI
0
35739 (68.0)
35546 (67.0)
0.0004
1
9319 (18.0)
9235 (18.0)
≥2
7411 (14.0)
7892 (15.0)
Rural, urban status: 6 observations with missing values
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Annual FOBT Use
Table 5 shows the annual FOBT use. During the period 2012-2016, the annual number of
members eligible for CRC screening fluctuated between 67,821 in the year 2012 to 79,544 in the
year 2014. In all years except in 2016, the number of eligible members was larger for rural
compared to urban areas. Overall, there was a small but significant decrease in the use of FOBT
between 2013 (11%) and 2016 (10%). Table 5 and Figure 16 display the results across all years.
One of the hypotheses under Aim 1 was that FOBT screening rate would be higher in the rural
population compared to the urban population. Findings suggest that rural members had higher
percentages of FOBT use (e.g., 11.39% vs. 10.76% in 2012) compared to urban members (P<.05).
Rural members had a consistently higher FOBT use for age groups 50-54 and 55-59, but
this pattern was reversed for the oldest age group of 60-64 years during the year 2016, where the
rural members had a higher use of FOBT. In rural areas, females had a consistently higher use of
FOBT compared to males. For instance, in 2012, 15% of females used FOBT while only 7% of males
used FOBT in rural areas. In urban areas, the use of FOBT was similar between males and females.
For both rural and urban areas, PCP visits were also related to the use of FOBT but with different
size of association. In rural areas in 2012, 12% of those who had PCP visits used FOBT while only
6% of those without PCP visits used FOBT. A similar pattern was observed for urban areas.
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Table 5. Annual Percentage of FOBT Use by Rural-urban Status, BCBSNE 2012–2016 (Aim 1)
2012
(n=8,527)
Overall by location
Characteristics
Age
50-54
55-59
60-64
Gender
Female
Male

2013
(n=8,827)

2014
(n=8,716)

2015
(n=7,870)

June, 2016
(n=7,229)

Rural
(n=4,706)

Urban
(n=3,821)

Rural
(n=4,827)

Urban
(n=4,000)

Rural
(n=4661)

Urban
(n=4,055)

Rural
(n=4,066)

Urban
(n=3,804)

Rural
(n=3,750)

Urban
(n=3,479)

11.39
(11.09,11.7)

10.76
(10.44,11.0)

11.54
(11.24,11.8)

10.69
(10.37,11.0)

11.50
(11.19,11.8)

10.39
(10.09,10.6)

10.67
(10.36,10.98)

10.23
(9.92,10.53)

10.63
(10.31,10.95)

9.47
(9.17,9.77)

11.69
(11.16,12.2)
11.95
(11.42,12.4)
10.44
(9.91,10.97)

9.82
(9.31,10.35)
11.47
(10.90,12.0)
11.09
(10.50,11.6)

11.80
(11.29,12.3)
11.94
(11.41,12.4)
10.77
(10.22,11.3)

9.70
(9.21,10.20)
11.35
(10.79,11.9)
11.16
(10.58,11.7)

11.73
(11.21,12.2)
11.82
(11.29,12.3)
10.83
(10.27,11.4)

9.40
(8.92,9.88)
11.01
(10.48,11.5)
10.93
(10.36,11.5)

10.86
(10.34,11.38)
10.98
(10.45,11.51)
10.05
(9.49,10.62)

9.30
(8.82,9.79)
10.84
(10.30,11.38)
10.69
(10.10,11.27)

10.92
(10.39,11.46)
11.01
(10.47,11.56)
9.74
(9.16,10.33)

8.77
(8.30,9.25)
10.13
(9.61,10.67)
9.58
(9.02,10.14)

15.0
(14.53,15.4)
7.34
(6.97,7.70)

10.99
(10.55,11.4)
10.47
(10.0,10.95)

15.18
(14.71,15.6)
7.47
(7.11,7.85)

10.91
(10.48,11.3)
10.42
(9.95,10.88)

15.18
(14.70,15.6)
7.40
(7.03,7.78)

10.61
(10.20,11.0)
10.12
(9.67,10.57)

14.34
(13.86, 14.82)
6.52
(6.16,6.88)

10.53
(10.11,10.95)
9.85
(9.40,10.30)

14.27
(13.76,14.77)
6.53
(6.15,6.90)

9.56
(9.16,9.97)
9.36
(8.91,9.81)

12.27
(11.92,12.6)
6.40
(5.79,7.02)

11.90
(11.54,12.2)
2.58
(2.11,3.05)

12.32
(11.98,12.6)
6.75
(6.10,7.39)

11.69
(11.34,12.0)
2.62
(2.13,3.11)

12.29
(11.94,12.6)
6.49
(5.84,7.15)

11.47
(11.14,11.8)
2.18
(1.76,2.61)

11.45
(11.10,11.80)
6.02
(5.39,6.67)

11.35
(11.01,11.70)
1.97
(1.56,2.38)

11.52
(11.16,11.88)
5.63
(5.01,6.25)

10.90
(10.55,11.24)
1.40
(1.09,1.71)

PCP visit
Yes
No
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Annual Colonoscopy Screening Use
Overall, colonoscopy use increased slightly from 14% in 2012 to 15% in 2015. Table 6 and
Figure 16 display the results across all years. The third row of Table 6 shows the annual
colonoscopy use by rural and urban status. One of the hypotheses under Aim 1 was that
colonoscopy rate would be higher in the urban population compared to the rural population. We
found that urban members had significantly higher percentages of colonoscopy use compared to
rural members (P<.001). The proportion of individuals who used colonoscopy was highest in the
youngest group (50-54 years) and lowest in the oldest group in both rural and urban areas. For
example, in 2012 in rural areas, 17% of people aged 50-54 used colonoscopy compared to only
9% of people aged 60-64 years. Similarly, in 2012 in urban areas, 18% of people aged 50-54 used
colonoscopy while only 11% of people aged 60-64 used colonoscopy.
In both rural and urban areas and across years, females had higher use of colonoscopy
compared to males. Moreover, among females, there were significant differences between rural
and urban areas where females who reside in urban areas had higher colonoscopy use; but the
magnitude of differences was small. Likewise, among males, there was small magnitude of
differences in the annual colonoscopy use. Further, we found differences between members who
had PCP visits compared to those who did not, and the differences were large (e.g., 15% vs. 5% in
2012). Among members who visited PCPs, urban members had higher colonoscopy use compared
to rural members. However, among members with no PCP visits, there were no differences
between rural and urban areas in the use of colonoscopy.
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Table 6: Annual Percentage of Colonoscopy Use by Rural-Urban Status, BDBSNE 2012-2016 (Aim 1)
2012
(n=10,855)
Overall by location

Characteristics
Age
50-54
55-59
60-64
Gender
Female
Male

2013
(n=11,421)

2014
(n=11,594)

2015
(n=11,164)

June, 2016
(n=10,502)

Rural
(n=5,595)

Urban
(n=5,258)

Rural
(n=5,757)

Urban
(n=5,662)

Rural
(n=5,721)

Urban
(n=5,871)

Rural
(n=5,473)

Urban
(n=5,689)

Rural
(n=5,116)

Urban
(n=5,385)

13.55
(13.22,13.88)

14.81
(14.44,15.18)

13.77
(13.44,14.10)

15.13
(14.77,15.49)

14.12
(13.78,14.46)

15.05
(14.69,15.40)

14.37
(14.01,14.72)

15.29
(14.93,15.66)

14.50
(14.13,14.87)

14.66
(14.30,15.03)

16.77
(16.17,17.38)
14.31
(13.73,14.89)
8.98
(8.48,9.48)

17.59
(16.93,18.25)
15.47
(14.82,16.13)
10.83
(10.25,11.42)

16.89
(16.29,17.49)
14.33
(13.76,14.90)
9.37
(8.86,9.88)

17.94
(17.30,18.85)
15.54
(14.91,16.18)
11.21
(10.63,11.80)

17.23
(16.62,17.84)
14.56
(13.98,15.15)
9.70
(9.16,10.23)

17.80
(17.18,18.43)
15.26
(14.64,15.87)
11.35
(10.77,11.93)

17.63
(17.0,18.27)
14.67
(14.07,15.26)
9.85
(9.29,10.41)

18.03
(17.39,18.67)
15.38
(14.75,16.01)
11.69
11.08,12.30)

17.75
(17.09,18.4)
14.87
(14.25,15.50)
9.72
(9.14,10.31)

17.44
(16.80,18.08)
14.63
(14.01,15.24)
11.12
(10.52,11.72)

14.56
(14.10,15.04)
12.40
(11.94,12.87)

15.94
(15.42,16.45)
13.42
(12.89,13.95)

14.83
(14.36,15.30)
12.58
(12.11,13.04)

16.28
(15.78,16.78)
13.71
(13.19,14.23)

15.21
(14.73,15.69)
12.90
(12.43,13.38)

16.22
(15.73,16.72)
13.59
(13.08,14.10)

15.33
(14.83,15.82)
13.28
(12.78,13.77)

16.45
(15.95,16.96)
13.87
(13.34,14.39)

15.40
(14.89,15.92)
13.48
(12.96,14.0)

15.53
(15.03,16.02)
13.58
(13.05,14.11)

15.08
(14.71,15.46)
4.76
(4.23,5.29)

16.23
(15.82,16.64)
4.58
(3.96,5.20)

15.16
(14.79,15.53)
5.21
(4.64,5.78)

16.35
(15.95,16.75)
5.24
(4.56,5.97)

15.46
(15.08,15.84)
5.52
(4.92,6.13)

16.35
(15.96,16.75)
5.11
(4.47,5.75)

15.84
(15.45,16.24)
5.51
(4.90,6.12)

16.66
(16.26,17.06)
5.28
(4.63,5.94)

16.13
(15.72,16.55)
5.33
(4.73,5.94)

16.46
(16.05,16.87)
4.46
(3.91,5.0)

PCP visit
Yes
No
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18%
16%

Percentage

14%
12%
Rural FOBT

10%

Rural Colonoscopy
8%

Urban FOBT
Urban Colonoscopy

6%
4%
2%
0%
2012

2013

2014

2015

2016

Figure 16. Annual Colonoscopy and Fecal Occult Blood Test in BlueCross BlueShield Nebraska
Population, 2012-2016
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Logistic Regression to Examine the Effect of Rural-Urban Status on FOBT Use
Logistic regression was used to assess the association between the prevalence of CRC
screening and the individual place of residence (rural or urban), and to compute the odds ratios
(ORs) and the 95% confidence intervals (CIs). Tables 7 and 9 show the ORs and the 95% CIs at the
univariate and the multivariate levels. The models were adjusted for age122,188-190, gender122,189,191,
PCPs visits120,189,192 and CCI56,193,194 based on prior literature demonstrating their association with
CRC screening.
As shown in Table 7, at the univariate level, rural population was 51% more likely to use
FOBT compared with the urban population. The female sex was associated with higher FOBT use
and the PCP visits (up to 5 visits during 2013-2014) were associated with higher FOBT use.
Multivariate analysis shows that rural members were 56% more likely to use FOBT compared with
their urban counterparts: [OR=1.56 (95% CI: 1.45, 1.69)]. The PCP visits was also significantly
associated with the FOBT use. Members who visited PCPs were more likely to use FOBT compared
to those who did not, and the FOBT use is higher among members with more PCP visits [OR=1.37
(95% CI: 1.21, 1.56)].
Moreover, because we identified interaction between rural-urban status and age, gender
and PCP visits, we stratified the analyses by these variables as displayed in Table 8. Among the
urban population, those who are 55-59 or 60-64 were more likely to use FOBT compared with 5054 years old [OR=1.20 (95% CI: 1.01, 1.41) and OR=1.30 (95% CI: 1.10, 1.54)]. Additionally, females
who live in urban areas were 15% more likely to use FOBT compared with males [OR=1.20 (95%
CI: 1.01, 1.41)], while those who live in rural areas were 68% less likely to use FOBT compared
with males [OR=0.32 (95% CI: 0.28, 0.36)]. Finally, PCP visits of up to 5 times within 2 years was
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associated with higher FOBT in the rural area while PCP visits was consistently (even > 5 visits)
associated with higher FOBT use in the urban area compared with no visits.
Table 7. Univariate and Multivariate Analyses of Variables Associated with FOBT Screening
Using Logistic Regression Models, BCBSNE 2013-2015 (Aim 1).
FOBT use in 2015
FOBT use
No FOBT use
PUnivariate
Multivariate
value
OR (95% CI)
OR (95% CI)
Age
50-54
729 (29.0)
17785 (32.0)
0.03
1.0
1.0
55-59
891 (36.0)
20056 (36.0)
1.08
1.05
(0.98,1.20)
(0.95,1.17)
60-64
863 (35.0)
18450 (33.0)
1.14
1.08
(1.03,1.26)
(0.97,1.19)
Gender
Male
803 (32.0)
26441 (47.0)
<.0001 1.0
1.0
Female 1680 (68.0)
29850 (53.0)
1.85
1.85
(1.69,2.04)
(1.69,2.0)
Member Status
Urban
952 (38.0)
27334 (49.0)
<.0001 1.0
1.0
Rural
1531 (62.0)
28955 (51.0)
1.51
1.56
(1.41,1.67)
(1.45,1.69)
PCP visits in
2013-2014
0

396 (16.0)

12703 (23.0)

1 to 2

646 (26.0)

15062 (27.0)

3 to 5

733 (30.0)

14796 (26.0)

6 to 9

457 (18.0)

8490 (15.0)

≥10

251 (10.0)

5240 (9.0)

0 1929 (78.0)
1 373 (15.0)

43847 (78.0)
7299 (15.0)

<.0001 1.0

1.0

1.38
(1.21,1.56)
1.59
(1.40,1.80)
1.73
(1.50,1.98)
1.54
(1.31,1.81)

1.37
(1.21,1.56)
1.59
(1.40,1.80)
1.71
(1.49,1.96)
1.49
(1.26,1.75)

1.0
1.02
(0.91,1.14)
0.99
(0.85,1.16)

1.0
0.99
(0.87,1.11)
0.95
(0.81,1.11)

CCI in
2013-2014

≥2

181 (7.0)

4145 (7.0)

0.92
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Table 8. Adjusted association between rural-urban status and FOBT use by age, gender and
PCP visits.
Rural-urban status
Age
Rural-urban status
50-54
55-59
60-64
Rural
1.0
0.97 (0.86,1.11)
0.96 (0.84,1.09)
Urban
1.0
1.20 (1.01,1.41)
1.30 (1.10,1.54)
Gender
Rural
Urban

Male
1.0
1.0

Female
0.32 (0.28,0.36)
1.15 (1.01,1.31)

PCP visits in 2013-2014
0
1 to 2
3 to 5
6 to 9
Rural
1.0
1.33
1.38
1.19
(1.15,1.55) (1.18,1.60) (0.99,1.42)
Urban
1.0
1.60
2.33
3.23
(1.25,2.05) (1.84,2.94) (2.53,4.12)
Adjusted for age, gender, PCP visits and CCI.

≥10
1.01
(0.81,1.25)
3.02
(2.29,3.98)

Logistic Regression to Examine the Effect of Rural-Urban Status on Colonoscopy Screening Use
As shown in Table 9, at the univariate level, the urban population was 9% more likely to
use colonoscopy compared with the rural population. The male sex was associated with lower
colonoscopy use while the PCPs visits 2013-2014 were associated with higher colonoscopy use.
Multivariate analysis shows that female members were 16% more likely to use colonoscopy
compared with male members: [OR=1.16 (95% CI: 1.09, 1.25)]. There was near significant increase
in the odds of colonoscopy use among urban versus rural population [OR=1.06 (95% CI: 0.98,
1.14)]. The PCP visits was also significantly associated with the colonoscopy use. Members who
visited PCPs were more likely to use colonoscopy compared to those who did not, and the
colonoscopy use was higher among members with more PCP visits [OR=1.36 (95% CI: 1.21, 1.52)].
Furthermore, the results of the stratified analyses by age are displayed in Table 10.
Among the rural population, those who are 55-59 or 60-64 were less likely to use colonoscopy
compared with 50-54 years old [OR=0.63 (95% CI: 0.55, 0.71) and OR=0.64 (95% CI: 0.56, 0.72)].
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Likewise, in the urban area, those who are 55-59 or 60-64 were less likely to use colonoscopy
compared with 50-54 years old [OR=0.43 (95% CI: 0.38, 0.49) and OR=0.67 (95% CI: 0.59, 0.75)].

83

Table 9. Univariate and Multivariate Analyses of Variables Associated with the Use of
Colonoscopy Using Logistic Regression Models, BCBSNE 2013-2015 (Aim 1).
Colonoscopy use in 2015 (Limited to screening colonoscopy) *
Colonoscopy No Colonoscopy P
Univariate
Multivariate
use
use
OR (95% CI)
OR (95% CI)
Age
50-54
1308 (43.0)
17206 (31.0)
<.0001 1.0
1.0
55-59
809 (27.0)
20138 (36.0)
0.53
0.56
(0.48,0.58)
(0.60,0.71)
60-64
926 (30.0)
18387 (33.0)
0.66
0.86
(0.61,0.72)
(0.80,0.93)
Gender
Male
1297 (43.0)
25947 (47.0)
1.0
1.0
Female
1746 (57.0)
29784 (53.0)
<.0001 1.18
1.16
(1.09,1.26)
(1.09,1.25)
Member Status
Rural
1515 (50.0)
28971 (52.0)
0.02
1.0
1.0
Urban
1528 (50.2)
26758 (48.0)
1.09
1.06
(1.01,1.17)
(0.98,1.14)
PCP visits in
2013-2014
0
521 (17.0)
12578 (23.0)
<.0001 1.0
1.0
1 to 2

834 (27.0)

14874 (27.0)

3 to 5

895 (29.0)

14634 (26.0)

≥6

793 (26.0)

13645 (24.0)

0
1

2415 (79.0)
439 (14.0)

43361 (78.0)
8233 (15.0)

≥2

189 (6.0)

4137 (7.0)

1.35
(1.21,1.51)
1.48
(1.32,1.65)
1.40
(1.25,1.57)

1.36
(1.21,1.52)
1.51
(1.35,1.68)
1.47
(1.31,1.65)

1.0
0.95
(0.86,1.06)
0.82
(0.70,0.95)

1.0
0.95
(0.85,1.05)
0.84
(0.71,0.97)

CCI in
2013-2014
0.03

*ICD DX codes for screening: 'V7651','Z1211','V7641','Z1212'

Table 10. Adjusted association between rural-urban status and colonoscopy use by age.
Rural-urban status
Age
Rural-urban status
50-54
55-59
60-64
Rural
1.0
0.63 (0.55,0.71)
0.64 (0.56,0.72)
Urban
1.0
0.43 (0.38,0.49)
0.67 (0.59,0.75)
Adjusted for age, gender, PCP visits and CCI.
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Aim2: The Impact of Travel Time on the Metastatic Stage at Diagnosis of
CRC
As shown in Figure 12 (Aim 2 Study Sample Selection Chart), a total of 307 individuals met
the eligibility criteria for this aim: aged 50-64 years, active members of BCBSNE during the study
period (2012-2016), had CRC diagnosis, and continuously enrolled for at least six months before
CRC diagnosis.
Univariate and Multivariate Analysis of Travel Time Analysis for Metastatic Stage at Diagnosis of
CRC
A total of 204 members were eligible for travel time analysis of whom 27 had metastatic
CRC and 177 had metastatic CRC (Table 11). Note the sample included BCBS members diagnosed
with CRC who had colonoscopy claim within four months before CRC diagnosis by metastatic
status. The average travel time among the 204 members with colonoscopy was 34 minutes
(SD=45). Approximately 25% of the members traveled within a time that is more than the mean
travel time. The relationship between travel time or rurality and metastatic CRC diagnoses were
not statistically significant. Therefore, the hypothesis “Shorter travel time to colonoscopy facility
is associated with a non-metastatic diagnosis of CRC” was rejected. Also, for those who do not
use preventive service, the odds of being diagnosed with metastatic CRC is 2.80 (95% CI: 1.00,
7.90) times larger than those who used preventive services.

85

Table 11. Univariate and Multivariate Analysis of Metastatic CRC Diagnosis (N=204) (Aim 2).
Metastatic
Non-Metastatic
Univariate
Multivariate
(n=27)
(n=177)
Model
Model
P
% or
% or
Odds Ratio
Odds Ratio
No
No
SD
SD
(95% CI)
(95% CI)
Age (year),
1.004
0.91
57.56
4.56
57.48
4.15
mean
(0.91,1.01)
Gender
Male

17

63.0

95

54.0

Female

10

37.0

82

46.0

Member
location
Rural

11

41.0

99

56.0

Urban

16

59.0

78

44.0

34.85

51.53

33.38

38.12

18.0

17.0

19.0

28.0

5

19.0

69

39.0

22

81.0

108

61.0

Travel time
(min), mean
Travel time
median (IQR)

1.0
0.68
(0.29,1.57)

0.37

1.0
0.76
(0.32, 1.80)

1.0
1.84
(0.82,4.20)

0.14

2.14
(0.87,5.30)
1.0

1.001
(0.99,1.01)

0.74

0.99
(0.98,1.01)

Preventive
services
Yes
No

1.0
2.81
(1.02,7.77)

1.0
0.04

2.80
(1.00,7.90)

Aim3: Rural-Urban Differences in Healthcare Utilization Among CRC
Patients
Hospital Readmission Following CRC Surgery
The first hypothesis under Aim 1 was “Urban CRC patients who undergo surgery are more
likely to have lower hospital readmission and emergency department visits.” As shown in Figure
13, the sample for this hypothesis consists of 315 patients who met the following eligibility
criteria: aged 50-64 years, active members of BCBSNE during the study period (2012-2016), had
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CRC diagnosis, continuously enrolled for at least six months before CRC diagnosis, and had CRC
surgery claims. The 30-day hospital readmission rate for this sample was 20%. The characteristics
of patients readmitted and those non-readmitted within 30 days of index surgery are presented
in Table 12. Readmitted patients were more likely to have higher Charlson Comorbidity Index 12
months prior to index surgery and with the slightly higher length of hospital stay after the
procedure. For instance, 18% of patients who were readmitted have had >1 comorbidities 12
months prior to index surgery versus only 7% of non-readmitted patients. There were no
statistically significant differences between the readmitted and non-readmitted patients
regarding age, gender, geographic location and travel time to the surgical facility. The median
length of stay was five days for readmitted patients versus four days for non-readmitted patients
although the results did not meet the 0.05 level of significance.
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Table 12. Patients Characteristics By 30-Days Readmission Status for Patients Who Survived
Index Hospitalization For Colorectal Cancer, BCBSNE 2012-2016 (Aim 3-H1, N=315)
Readmitted
Non-readmitted
P
No
% or SD
No
% or SD
Overall
62
20
253
80
Age, mean

54

8.32

53.95

7.96

0.92

Gender
Female
Male

24
38

39
61

105
148

42
58

0.69

Member Location
Rural
Urban

26
36

42
58

135
118

53
47

0.11

Distance to provider
Mean
Median

21.91
16.00

26.25
19.50

22.78
11.05

40.31
21.75

0.29

Travel time
Mean
Median

27.69
21.00

27.19
24.00

27.92
17.00

40.46
24.00

0.22

Length of stay
Mean
Median

6.42
5.00

5.21
5.00

5.46
4.00

5.72
3.00

0.07

Charlson Comorbidity Index
prior to surgery
0
1
>1

33
18
11

53
29
18

171
64
18

68
25
7

0.02

A further analysis was conducted to compare characteristics of index surgery between
patients with readmission and patients without readmission (Table 13). There were no significant
differences between readmitted and non-readmitted patients in the site of the tumor, the site of
surgery or whether the patients underwent stoma. However, readmitted patients were more
likely to have undergone open surgery and were more likely to have presented with obstructed
or perforated colon. Specifically, 77% of the readmitted patients underwent open CRC surgery
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while only 50% of the non-readmitted patients underwent open CRC surgery. Furthermore, 58%
of the readmitted patients had obstructed or perforated intestine during the index surgery versus
16% for non-readmitted patients.
Table 13. Index Surgery Characteristics By 30-Days Readmission Status for Patients Who
Survived Index Hospitalization For Colorectal Cancer, BCBSNE 2012-2016 (Aim 3-H1, N=315)
Readmitted
Non-Readmitted
No
%
No
%
P
Tumor location
Colon
38
61
168
66
0.45
Rectum
24
39
85
34
Surgery site
Proximal
Distal
Rectal /other

12
23
27

19
37
44

45
97
111

18
38
44

0.95

Surgery approach
Laparoscopic
Open

14
48

23
77

127
126

50
50

<0.0001

Intestinal obstruction or
perforation on admission
Yes
No

36
26

58
42

41
212

16
84

<0.0001

Stoma creation
Yes
No

22
40

35
65

61
192

24
76

0.07

After adjusting for Charlson Comorbidity Index, surgical approach and obstruction status
there was no evidence of a difference in the odds of readmission for rural versus urban patients
(Table 14). Therefore, the hypothesis about the rural and urban difference for readmission was
rejected. Patients with Charlson Comorbidity Index >1, those with the open procedure and those
who presented with obstruction or perforation at the time of surgery were more likely to be
readmitted.
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Table 14. Multivariable Analysis of Risk Factors for 30-Day Readmission, BCBSNE 2012-2016
(Aim 3-H1).
OR
(95% CI)
Member Location
Rural
1.0
Urban
1.81
(0.96,3.42)
Charlson Comorbidity Index
0
1
>1

1.0
1.11
3.59

(0.45,2.30)
(1.41,9.11)

Surgery approach
Laparoscopic
Open

1.0
2.80

(1.39,5.63)

Intestinal obstruction or
perforation on admission
No
Yes

1.0
7.17

(3.75,13.72)

The Utilization of CRC Surgery Among Patients with Metastatic CRC
The second hypothesis under Aim 3 was “Among patients with metastatic CRC, the
proportion who undergo surgery is higher among the urban population compared with the rural
population.” As shown in Figure 14, the sample for this hypothesis consists of 69 patients who
met the following eligibility criteria: aged 50-64 years, active members of BCBSNE during the study
period (2012-2016), had metastatic CRC diagnosis and continuously enrolled for at least six
months before CRC diagnosis.
Current NCCN guidelines recommend that patients with symptomatic mCRC undergo PTR.
Asymptomatic patients can be treated with either systemic therapy or surgical intervention (see
Chapter 2 for more details). The proportion of rural patients who underwent mCRC surgery is
significantly lower than the proportion of urban patients with mCRC (Table 15). Therefore, the
hypothesis was not rejected. For example, 39% of members who underwent metastatic CRC
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surgery lives in rural areas versus 61% who lives in urban areas. Patients who underwent mCRC
surgery tend to be older than 50 years old (87%), male (63%), urban residents (61%), had higher
Charlson Comorbidity Index 12 months prior surgery (82% for CCI≥1) and were diagnosed with
colon cancer (73%).
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Table 15. Characteristics of Patients with Metastatic CRC (mCRC) By Surgery Uptake, BCBSNE
2012-2016 (N=69) (Aim 3-H2).
With mCRC Surgery
No mCRC Surgery
No.

% / SD

No.

% / SD

33

47

36

52

54.49

8.28

54

8.83

0.81

<50

4

12

7

19

0.40

50-64

29

87

29

80

Female

12

36

18

50

Male

21

63

18

50

Rural

13

39

25

69

Urban

20

61

11

31

0

4

12

11

31

1

18

55

11

31

>1

11

33

14

38

Mean

30.76

27.23

34.39

36.09

Median(IQR)

22.00

21.00

24.00

38.00

Colon

24

73

28

78

Rectum

9

27

8

22

Liver

14

42

13

36

Others

19

58

23

64

1 site

16

48

20

56

>1 site

17

52

16

44

Overall
Age (mean)

P

Gender
0.25

Member location
0.01

CCI
0.08

Travel time
0.93

Primary tumor site
0.62

Site of metastasis
0.59

No. of metastatic sites
0.55

Access to PCP services
Mean (physician/10,000)

11.31

10.35

10.96

8.17

Median(IQR)

8.15

9.11

8.15

10.69

0.86
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Logistic Regression Results of the Receipt of Metastatic CRC Surgery
After adjusting for gender and Charlson Comorbidity Index (Table 16), urban CRC patients
were more likely to undergo mCRC surgery compared with rural CRC patients 4.35 (95% CI: 1.40,
13.49).
Table 16. Multivariable Logistic Regression for Location Adjusted for Gender and Charlson
Comorbidity Index, BCBSNE 2012-2016 (Aim 3-H2)
OR 95% CI
P
Gender
Female
1.0
0.07
Male
2.84 (0.90,8.95)
Member Location
Rural
Urban
Intestinal obstruction or
perforation on admission
No
Yes
CCI
0
1
>1

1.0
4.35 (1.40,13.49)

1.0
1.88 (0.52,6.80)
1.0
4.36 (1.03,18.53)
2.22 (0.50,9.84)

0.01

0.34

0.05
0.91

Sphincter Sparing Surgery Among Patients with Rectal Cancer
The last hypothesis for Aim 3 was “Among rectal cancer patients, the proportion who
undergo sphincter-preserving surgery is higher among the urban population compared with the
rural population.” As shown in Figure 15, the sample for this hypothesis consists of 90 patients
who met the following eligibility criteria: aged 50-64 years, active members of BCBSNE during the
study period (2012-2016), had a rectal cancer diagnosis and continuously enrolled for at least six
months before CRC diagnosis. Three-quarters of the patients diagnosed with rectal cancer and
treated surgically underwent sphincter-sparing surgery. There were no significant differences in
the characteristics of patients including rural residency (Table 17). Therefore, the hypothesis was
rejected.
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Table 17. Characteristics of Patients with Rectal Cancer by Type Of Surgery, BCBSNE 2012-2016
(N=90) (Aim 3-H3)
Sphincter
Non-Sphincter
Sparing Surgery
Sparing Surgery
No.
% / SD
No.
% / SD P
Overall
69
77.0
21
23.0
Age, mean

52.10

8.56

53.38

10.37

0.24

Gender
Female
Male

33
36

48.0
52.0

7
14

33.0
67.0

0.24

Member Location
Rural
Urban

33
36

48.0
52.0

10
11

48.0
52.0

0.99

CCI
≤1
>1

32
37

47.0
53.0

9
12

43.0
57.0

0.78

Distance to provider (miles)
Mean
Median

16.51
12.40

16.70
20.50

24.61
5.90

61.80
16.10

0.38

Travel time (minutes)
Mean
Median

21.27
19.0

18.08
22.0

28.33
16.0

55.60
25.0

0.38

Surgery approach
Laparoscopic
Open

39
30

57.0
43.0

11
10

52.0
48.0

0.74
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CHAPTER 5: DISCUSSION

Summary of Findings
To our knowledge, this is one of the few published studies that used privately-insured
data to investigate the differences between the rural and the urban populations in CRC screening
rates, stage at diagnosis and the receipt of surgery. In this privately insured population, there was
an overall significant increase in the colonoscopy use between 2012 and 2016 (14% to 15%) and
an overall decrease in FOBT use between 2013 and 2016 (11% to 10%). While the urban
population was more likely to use colonoscopy, the rural population was more likely to use FOBT.
Although the percentage changes in screening were significant, the changes were small. When
adjusting for covariates, the rural population was 56% more likely to use FOBT compared with the
urban population.
Although there was no association between travel time to a colonoscopy facility and
metastatic stage at diagnosis, we found that patients who had no preventive services (vs. those
who had preventive services) to be 2.80 times more likely to present with mCRC. Additionally, for
the utilization of mCRC surgery, we found that the urban population was 4.35 times more likely
to receive mCRC surgery compared to their rural counterpart, but there was no significant
difference in the receipt of SSS or the 30 days hospital readmission between the two populations.
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Colorectal Cancer Screening in BCBSNE Population by Rural and Urban
Status
Prior research on CRC indicates that screening reduces both incidence and mortality rates
by detecting polyps or tumors at a precancerous or early stage.58,195 In spite of the demonstrated
effectiveness of CRC screening tests, CRC screening rates remain less than optimal. In 2015, only
62.4% of Americans who were eligible for screening received one of the recommended screening
tests, which is lower than the 80% target set by the Centers for Disease Control and Prevention’s
Colorectal Cancer Program.196
Our findings of the declining use of FOBT and the increasing use of colonoscopy are similar
to other studies.12,86 These studies have the same age group as our study (50-64 years old). While
one of the studies used claims data the other used survey data and both used data from earlier
period (1998-2005). Furthermore, we found that the annual FOBT use was between 10% and 11%,
which is slightly higher than recent FOBT rates from national surveys. For example, the latest rates
from BRFSS in 2014 and NHIS in 2015 were 8% and 6%.3,13,16 The differences in FOBT rates could
be due to the differences between claims and self-reported data such as the survey.197,198 For
instance, studies that are based on surveys are prone to recall bias.197,198Additionally, some of the
population surveyed are uninsured or underinsured, which might result in lower screening rates.
.
In this study, the annual colonoscopy rates were fluctuating between 14% in 2012 and
15% in 2016. Among the Medicare population who were 50-64 years old, Schenck et al. found
that the annual colonoscopy rates were increasing from 5% in 1998 to 9% in 2005. Their findings
is the latest comparable rates because recent (non-comparable) rates are based on ten years data
and combine the endoscopy tests (colonoscopy and sigmoidoscopy), which is hard to compare
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with the annual rates reported in this study.12,199 For instance, the 2015 NHIS data showed that
55% of the surveyed individuals (50-64 years old) had used sigmoidoscopy within the past five
years or used colonoscopy within the past ten years.13 Likewise, the 2012 BRFSS data showed that
65% of the survey individuals (all age groups) reported that they ever had an endoscopy.87
We examined factors associated with FOBT and colonoscopy use. We found that the FOBT
screening across age groups did not change between 2012 and 2016. However, age was an
important factor in the use of colonoscopy because there was a large difference in the use of
colonoscopy between the younger and older individuals across the years. For instance, in 2016
the use of colonoscopy was 17% among the 50-54 years old, 15% among the 55-59 years old and
11% among the 60-64 years old. This pattern observed across the entire study period. It is possible
that the younger age group are more likely to initiate CRC screening once they turn 50 years old
compared with older individuals. Furthermore, after adjustment for age, gender and PCP visits,
there was no difference in the use of FOBT or colonoscopy between males and females. Although
studies that used data from 1999 or 2000 reported that males were more likely to use screening,
87,200,201

recent studies from 2012 and 2013 showed no difference in the use of CRC screening

between males and females.87,88
When placed in the context of primary care literature, our findings corroborate results
from several studies.84,179,202,203 In our study, both univariate and multivariate analyses showed
that higher PCP visits are associated with significantly higher FOBT and colonoscopy screening.
Ata and colleagues assessed the impact of time since last doctor visit on CRC screening and found
that the odds of screening decrease according to the last time of doctor’s visit.202 Compared with
those who had doctor visits more than 2 years, the odds ratio for those with a visit within six
months, between six months and one year and between 1-2 years were 7.59, 5.86 and 2.76.202
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Studies from 30 primary care practices found both FOBT and colonoscopy were increasing with
the increase in the number of PCP visits.203 Moreover, we found that FOBT use is more common
in women compared to men [OR=1.85 (95% CI: 1.69, 2.0)]. This is similar to other studies that
assessed the difference in CRC screening between males and females,189,204 though other study
found similar use.122 We also found that females are more likely to use colonoscopy compared to
males. This is different from previous studies that found male reported higher use.122,189 Part of
the inconsistent findings is due to the methodology used in previous studies. For example, some
studies combined all endoscopy test, others did not distinguish between the purpose of
colonoscopy test (i.e., screening versus others), while others measure colonoscopy use in previous
ten years. Our results are not directly comparable with results from survey data because we only
have access to shorter period (<10 years).

Travel Time and Metastatic Stage at Diagnosis of CRC
The reason to conduct this analysis was based on the idea that, unlike Medicare
population, the younger working-age population are less motivated to travel to a colonoscopy
facility to receive screening test and therefore are more likely to present with metastatic
CRC.190,205,206 In the current study, we also examined the roles of the use of preventive services as
the rural population characteristics are different from the urban population and the access to
services is a big concern in the rural areas.
There was no significant association between rural residence and the late stage diagnosis
of CRC in the current study. This is similar to results from recent studies that used cancer registry
data from Iowa, Nebraska, and Geogia106,111,118 with the exceptions from a registry study
conducted in Illinois.207 In addition, our study did not find a significant association between travel
time and metastatic CRC. The findings from this study confirm the results from studies that used
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cancer registry data.118,208 It was unexpected to find no association between rurality and distance,
and late-stage diagnosis especially that BCBSNE rural residents are significantly less likely to
undergo screening colonoscopy compared with the urban residents. Additionally, survey data
indicate a lower adherence rate of CRC screening among rural residents compared to urban
residents.86,88 A potential explanation for the lack of association is because the magnitude of
difference in screening between the rural and the urban is small (e.g., in 2012 the colonoscopy
use among rural residents was 13.55% and among urban residents was 14.81%). Subsequently,
this small difference is not translated into differences in CRC stage at diagnosis. Alternatively, the
discrepancy could be explained by the differences between registry and claims data versus survey
data. Surveys might results in potential biases (e.g., recall bias) while registry data, as well as
claims-based data, are more valid because of the accuracy of reporting for registry and because
claim’s reimbursement is conditional on patient’s health-encounter.
Results on the role of preventive services give some insight on the importance of CRC
prevention. We found that patients who did not use preventive services within 12 months before
CRC diagnosis were two times more likely to get diagnosed with metastatic CRC compared to
those who had such services. The result may reflect the notion that cancer screening
communication between the patient and the provider may occur during an annual checkup or
other routine care settings.64,209,210 It is also possible that patients who perceive screening as less
beneficial are less likely to use other types of preventive services.123,211 The health belief model,212
which was developed to elucidates health behavior changes, has extensively been used in cancer
screening literature.211,213 Using the model, prior research found that the construct of ‘perceived
benefits’ to be associated with more screening uptake.188,214-216 This finding is similar to other
diseases as well (e.g., breast cancer) such that the more health-conscious an individual, the more
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likely such individual is to seek healthy behaviors including preventive services such as
screening.194

Rural-Urban Status and Hospital Readmission After CRC Surgery
Our retrospective cohort study of the privately-insured adults who were diagnosed with
CRC and treated surgically over the period from January 2012 to June 2016 resulted in 20%
readmission rate and 6% emergency department visit. The readmission rates that have been
reported in the literature are ranging between 9% and 25% and the emergency department visit
around 7% and 9%.180,181,217 The consequences of readmission can be serious since those
readmitted within 30 days of the index surgery have 2.44 increased in the odds of mortality
compared with those who were not readmitted.161 In this study, the rural-urban status was not a
predictor factor for 30-day hospital readmission. This finding is similar to a study conducted
among Medicare population that found no differences between the rural and urban populations
in the 30-day readmission rates.161 However, it is dissimilar to another study which found that
rural population is more likely to get readmitted.160
Part of the discrepant findings could be because of different definitions for readmission
depending on the data source used. For example, National Surgical Quality Improvement Program
(NSQIP) uses clinical reviewer to check medical records for postoperative complications that
derive readmission and use phone calls to follow up with patients. However, the University Health
System Consortium (UHC) database is a discharge billing data set that is limited to inpatient
records.218 Another difference is that NSQIP defines readmission starting from the date of surgery
while UHC uses the day after discharge.218 Moreover, surgery volumes were not measured in the
current study and therefore we were unable to adjust for it in the analysis.
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Among the risk factors of 30-day readmission identified in this study are the use of open
surgery approach, Charlson Comorbidity Index (CCI) score of >1 and the presence of obstruction
or perforation at the time of admission. Since the introduction of laparoscopic CRC surgery in
1991,219,220 the association between the laparoscopic CRC surgery (versus open approach) and the
decreased readmission rates has been debated. The impact of the surgical approach on the risk
of hospital readmission after CRC surgery is somewhat anticipated. Although the laparoscopic
procedure is associated with longer operation time, several studies have found that the minimally
invasive laparoscopic approach is associated with favorable outcomes including lower
readmission rates.180,221 As a result, there has been an increase in the utilization of laparoscopy
during the CRC surgery (37% in 2008 and 44% in 2011).222 Additional favorable outcomes
associated with the laparoscopy use are a lower postoperative pain, shorter duration of ileus,
improved pulmonary function, better overall quality of life during the 30 days postoperatively and
less postoperative LOS.221 The latter have been found to be associated with lower 30 days hospital
readmission; in the current study, we found near-significant higher LOS among readmitted
patients (P=0.07).
In our study, we found that patients who underwent open surgery had 2.8 the odds of
being readmitted to the hospital within 30 days of the index surgery compared to those who
underwent laparoscopic surgery; 2.8 (95% CI: 1.39, 5.63). Congruent with our findings, Damle et
al. assessed the association between surgery approach and 30 days readmission and found that
patients who underwent open surgery to be 24% more likely to get readmitted compared to those
with laparoscopic surgery; 1.24 (95% CI: 1.17, 1.31).102 Likewise, Bartlett et al. found that patients
who underwent laparoscopic surgery to be less likely to get readmitted; 0.90 (95% CI:
0.85,0.96).163 However, other studies reported non-significant findings.162,165,167 Therefore, given
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that the higher the use of the laparoscope the lower the LOS, and that the lower the LOS the lower
the hospital readmission, the evidence suggests an association between laparoscopic use and the
lower readmission rate.
We also found that patients with >1 comorbidity score within 12 months before surgery
to be 3.59 more likely to get readmitted to the hospital within 30 days after index surgery. Several
studies from diverse populations found that the higher the comorbidity, the higher the likelihood
of readmission.159,160,163,223 Comorbidity is associated with higher mortality, lower quality of life
and higher complications of treatment.224 For instance, Greenblatt and colleagues found that
patients who were readmitted within 30 days of discharge to be 2.44 more likely to die compared
to those who were not readmitted after controlling many variables including comorbidities.161
Lastly, we found that 24% of readmitted patients had obstructed or perforated bowel at
the time of index surgery. This is slightly higher than some studies,139 but similar to others.225,226
Part of the differences could be different age groups among these studies. Patients with
obstructed or perforated bowel were 7.17 more likely to get readmitted to the hospital within 30
days after index surgery, which is similar to some studies that found worse outcomes associated
with patients who are presented with obstructed or perforated tumors.155,161

Rural-Urban Status and Differences in Surgery Utilization Among Patients
with Metastatic CRC
Due to the higher likelihood of cure, the current National Comprehensive Cancer Network
(NCCN) guidelines recommend the surgical resection of the metastatic tumor in CRC patients with
resectable metastases.67 Several studies have shown a 5-year disease-free survival of 20%, and
meta-analysis reported a median survival of 38%.227-231 Additionally, numerous studies have
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demonstrated a 5-year overall survival of up to 71% following resection for patients with liveronly metastasis.232-234 Almost half of the metastases that occur among CRC patients take place in
the liver, up to 25% in the lung and the rest occur in other organs. Since most of the CRC deaths
occur in patients with mCRC and because chemotherapy is not a curative treatment for mCRC,
surgical intervention is the only cure for mCRC patients.235
While 61% of our study population who were living in the urban area underwent mCRC
surgery, only 39% of those who were living in the rural area underwent mCRC surgery. In the
multivariate analysis, we found that urban population is 4.65 times more likely to receive mCRC
surgery compared to their rural counterparts. Hu and colleagues assessed the secular trends of
primary tumor resection among patients with metastatic CRC between 1988 and 2010 using
elderly population. The authors found a decrease in the surgery use from 67.4% and 57.4%. Half
of patients who live in the West underwent tumor resection and 15.9% of patients who live in the
Midwest received the surgery. However, the study didn’t distinguish patients’ rural-urban status.
There are several possible explanations for the difference in mCRC surgery rates between
the rural and the urban populations. First, given the complexity of the surgical resection of
metastatic tumors and the required multidisciplinary expertise especially for rectal cancer,74 rural
hospitals are possibly less equipped with such resources. Although current treatment guidelines
will minimize regional variations in surgery uptake, access to technology, surgeon’s supply, and
patients’ own belief are potential determinants of utilization.73,236 Second, it is possible that some
patients at rural hospitals presented with asymptomatic unresectable tumors, NCCN guidelines
recommend against operating on such patients, hence the lower rate of rural surgery reported in
our study assuming that surgeons adhere to such guidelines.
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Rural-Urban Status and Differences in Sphincter-Sparing Surgery (SSS)
Utilization Among Patients with Rectal Cancer
In resemblance to sphincter-sacrificing surgery, sphincter-sparing surgery (SSS) for rectal
cancer is associated with comparable oncological outcomes. Both procedures lead to similar rates
of tumor recurrence and equivalent rates of survival.237 However, SSS is associated with better
patients’ satisfactions and lower morbidity. For example, the social, psychological and physical
well-being is better among patients treated with SSS.81,83 Because of the better outcomes
associated with SSS, the rate of SSS have steadily increased between 1988 and 2006: 27% in 1988
and 60% in 2006. In our study, the rate of SSS use is 77%.
We found that the rate of SSS uptake is similar in both the rural and the urban privatelyinsured populations. Paquette and colleagues assessed the association between rural residents
and SSS utilization and found that urban patients are more likely to receive the surgery.108
Although authors controlled for the effect of hospital procedure volumes, the discrepancy in
procedure volume between hospitals did not explain the higher SSS uptake in urban residents.
According to the authors, although the SSS rates increased in both the rural and the urban areas,
the rates remained higher among the urban population. In our study, given that patients are
privately-insured, it is possible that the null finding is due to higher access to treatment among
the rural and urban populations. One also can speculate that the no difference findings in this
study could be due to an increase in the SSS uptake due to the overall better outcome.

Strengths and Limitations
Claims-based data are type of data that issued by institutions and providers for
reimbursement purposes.238,239 Examples of such institutions are insurance firms, healthcare
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systems or government agencies. The purpose of collecting the data is for organizing, tracking
patient health and interaction with the healthcare system. As a result, claims data are not
collected for research purposes. Instead, the ideal data source for cancer outcome and treatment
would be the clinical trials. This type of data allows investigators to have detailed clinical
information about patient’s comorbidities and possible preventive or risk factors.240,241 The lack
of selection bias in such data ensures that the relationship between predictors and outcome is
not confounded. Unfortunately, only 3%-5% of adult cancer patients are enrolled in clinical
trials.242
Unlike clinical trials, claims-based data represent a large population since they contain
thousands of insured individuals.239,243 Given that, it is an ideal data source for investigating rare
outcomes such as cancer. Claims-based data include extensive demographic information,
procedure and treatment information, and providers or organizational characteristics. Unlike data
generated from clinical trials, claims data are readily available, relatively less expensive and reflect
the usual care for patients. Studies that assessed the accuracy of claims data in comparison with
medical records found high validity.243
In addition to their uniqueness, claims data have several limitations.238,244,245 They lack key
clinical variables. For instance, claims data do not contain information about cancer staging
because the reimbursement process is not conditioned on disease characteristics.238 Further, not
all diagnoses and procedures are captured in claims data. In general, the higher the
reimbursement of a specific procedure, the more likely for such procedure to be captured in the
data. For instance, major surgeries are more likely to be captured while comorbidities are less
likely. Likewise, lab results that are not covered or reimbursed are usually not captured.
Moreover, access to claims data can be prohibitive because of the data user agreement, requires
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substantial learning-curve and programming skills, high patient turn-over, contain procedure
information but without results, delay in data release (time lag) and the study design might impact
data sensitivity and specificity.
Accordingly, there are specific limitations that should be considered when interpreting
the findings of this study. First, about 2% of BCBSNE members ended their membership during
December 2014, although the impact is minimal, it is possible that this might have contributed to
the lower screening rates, compared to the year 2015, especially assuming that some of those
who left BCBSNE were eligible for CRC screening. Second, because claims data are used mainly for
billing purposes, they do not distinguish the type of colonoscopy use (screening versus none
screening).246 However, we were able to exclude high-risk populations (e.g., with previous CRC
diagnosis, IBD, polyps, and UC) and thus were able to limit our population to average-risk
individuals who are more likely to use screening colonoscopy. We also restricted our population
to those with continuous enrollment to ensure that the exclusion criteria were met.
Third, we excluded 30% of the study sample from the travel time analysis because we
were not able to identify colonoscopy claims within four months prior to CRC diagnosis for these
individuals. A potential explanation is that some of these patients were diagnosed at the time of
surgery due to an obstructed colon. Nonetheless, excluded cases were not significantly different
from the ones that were not excluded in all measured characteristics in this study. Fourth, we
were uncertain about the intent of colonoscopy test because classifications were based on claims
that occurred within 4-months prior to diagnosis; thus, it is possible that misclassification might
have occurred if symptoms happened before this time or they have never been captured in the
data. Fifth, findings should be interpreted with cautions since the six months period for
identifying preventive services use might not entirely capture the health behavior of an individual.
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For instance, one might use more health services only during or after an acute illness and thus,
will be less likely to be captured within the window of six months. Ideally, we should examine the
preventive services use within one or two years of CRC diagnosis.56,183
Sixth, we were unable to adjust for hospital volume when assessing the association
between rural-urban status and surgery uptake because the hospital data are not linked to
patient’s data. Seventh, BCBSNE provides no information about the intent of PTR; therefore, it is
possible that patients could have undergone resection as palliative therapy or PTR with the
resection of the metastatic tumor as curative intent. Eighth, although the BCBSNE population
represents the population of Nebraska fairly well, this privately insured population does not
include the underinsured or uninsured population of Nebraska. Thus, one should be cautious
when comparing BCBSNE to findings from survey studies that included both insured and
uninsured populations. Lastly, due to the low statistical powers for aim 2 and aim 3, our findings
for these aims should be interpreted cautiously.
The implication of using claims data to answer research question include their effect on
information bias, selection bias or confounding. For instance, information bias might arise if
underreported diagnosis or procedure are used which will lead to biased effect estimate. In this
study, we expect that such bias might lead to non-differential misclassification. Another example
is the occurrence of confounding by indication. This type of selection bias can occur if patients
selected for treatment are different from those who are not. The selection process is either
motivated by clinical indication or via referral (e.g., complex cases are referred to certain
hospitals).
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Conclusion
In our privately-insured population in Nebraska, FOBT screening use is higher among rural
population while colonoscopy screening is higher among the urban population. There are
profound disparities by gender, the use of preventive services and by PCP visits. To increase CRC
screening use, patients should be educated about the benefits of CRC screening including the fact
that more convenient and less expensive tests are readily available. The discussion can be initiated
during PCP visits when the use of preventive services is more likely to be discussed at the checkup
visits. Given that the CRC is a preventable disease, it is also imperative to educate patients about
the risk factors for CRC since around 40% of the disparities in CRC incidence is attributed to
differences in the prevalence of risk factors such as smoking, unhealthy diet, and obesity. 247,248
This study did not find an association between travel time to the colonoscopy service and
the diagnosis of the metastatic CRC. The fact that 13% of this privately insured working-age
population present with metastatic CRC suggests some non-compliance with screening
guidelines. It is also possible that in this young cohort population some cases present with the
aggressive and fast-growing form of the disease with the potential development of mCRC
between screening colonoscopies. Nevertheless, it is possible that this working-age population
faces logistic barriers that prevent them from getting off work to get screened.190,205,206
Alternately, this young cohort population might have a lower perceived risk of getting CRC
compared with the older population and thus forgo screening.
The 30-day readmission occurs in about 20% of our population. The identified predictable
factors were patients who underwent an open procedure, those presented with obstructed or
perforated colon and patients with higher comorbidities. Hospital readmission is a quality of care
indicator for patients with CRC and identifying the most predictor factors is crucial to preventing
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readmission. For patients diagnosed with mCRC, we found no major differences between patients
with and those without surgery. Despite that, the urban population is more likely to undergo
surgery. These findings indicate an underuse of mCRC surgery among the rural population. For
patients diagnosed with rectal surgery, the majority (77%) underwent SSS, but we did not find an
association between rural-urban status and the SSS use.

Implications and Recommendations
Colonoscopy is the gold standard screening test and all other screening tests with positive
findings must be followed by colonoscopy. In this study, patients with screening colonoscopy were
less likely to be diagnosed with metastatic CRC compared with those who used surveillance or
diagnostic colonoscopy. Accordingly, we recommend alleviating barriers that prevent rural
patients from getting screening-colonoscopy and therefore increase the likelihood of early
detection of CRC. Until these obstacles have been lessened, screening with more convenient tests
should be encouraged. One option would be to encourage the use of mailed FOBT/FIT screening
test since screening with any test that is recommended by the guidelines is better than no
screening. This type of CRC screening is more convenient because it is taken at home and does
not require a visit to the healthcare provider.249 In particular, FIT does not require dietary
restriction and thus can be easily accepted by patients. Whereas specialists with training in
colonoscopy are needed, PCPs can prescribe FOBT/FIT tests and thus facilitate more CRC
screening.
There are many implications for the associations between rural-urban status and 30-day
hospital readmission. We found that readmission occurs frequently, and some predictor factors
are preventable. For instance, patients with ≥2 comorbidities were more likely to be readmitted.
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Institutions should adopt the use of risk prediction calculator to be able to expect the most
common readmission predictors.250,251
For patients diagnosed with mCRC, our findings indicate that there is unawareness or
disagreement with current guidelines among surgeon in rural areas. The unawareness is
concerning since the studied patients have similar characteristics. For patients diagnosed with
rectal surgery, the study indicates a similar use of SSS between the rural and urban populations.
More than half of the patients in this study underwent laparoscopic SSS, which found to be
associated with better oncologic outcomes (e.g., surgical margins or lymph node harvest)
compared with open surgery. Although not captured in BCBSNE, better outcomes can be achieved
by the use of robotics.80

Suggestions for Future Research
Integrated healthcare or organized delivery system is a network of organizations that
coordinate continuum of services to a defined population and is willing to be held clinically and
fiscally accountable for the outcomes and the health status of the population it served.252 In this
integrated healthcare, we found that members with a higher number of PCP visits had higher
rates of CRC screening. It is, however, unknown if other unmeasured factors have contributed to
the increased CRC screening. For example, population outreach efforts (e.g., FIT/gFOB Kit
distribution) or system that are used to invites for screening could have contributed to the
increased CRC screening uptake. Future studies should illuminate the mechanism of CRC
screening uptake other than PCP visits. In this population, it is yet to be determined if other
mechanisms play a role in CRC screening uptake and the extent of their future potential in CRC
prevention. Identifying the mechanism of CRC screening and their extent in eliciting CRC screening
will be useful for interventions to increase public health awareness and uptake of CRC screening.
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Additional avenues for future research should shed light on the “follow-up screening”
during the CRC screening detection process. For instance, given the importance of following up
patients with positive FOBT, it is imperative to see what proportion of such population will
undergo colonoscopy screening. Because claims data does not report the findings of the tests (i.e.,
positive /negative FOBT), we encourage future researchers to ascertain the proportion of test
completers through linking claims data with electronic health records. Determining the
percentage of test completers is feasible in integrated health system such as BCBSNE because
those with positive FOBT will be more likely, assuming they undergo colonoscopy screening, to
remain within the same insurers since the majority of follow up colonoscopy occur during the
three months of positive FOBT.253
Further, in this study, we found that women are more likely to undergo FOBT test
compared to men. We also found that there was an interaction between rural-urban status and
gender such that females in the rural areas are less likely to use FOBT while females in the urban
areas are more likely to use FOBT. Although this finding has been reported previously, it is unclear
why such disparity in access to FOBT use exist among women in a privately-insured population.
Future studies should elucidate factors associated with gender differences in FOBT screening
among the urban and the rural populations.
Future studies should also acknowledge the limitations of claims data and work to
mitigates such limitations. For example, since claims data lack information about the stage at
diagnosis information, the linkage of Nebraska Cancer Registry with the BCBSNE data in future
studies is warranted. Unlike claims data, cases ascertainment in registry data is more optimal and
with less likelihood of selection bias. Although previous research showed that claims data are
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associated with improved validity using ICD codes,175 registry data is the gold standard and would
complement the available variables in BCBSNE data.
The current study was limited to annual screening rates because we had access to 4.5
years of BCBSNE data. Future studies should obtain 6-11 years of data to measure CRC screening
rates according to the USPSTF guidelines. Given that sigmoidoscopy is recommended every five
years, a period of at least six years would be ideal to operationalize sigmoidoscopy use. Likewise,
the 11 years period would be enough to compute colonoscopy use in this privately-insured
population. Moreover, future studies with enough data should design a matched retrospective
cohort study to assess the association between rural-urban status and CRC surgery uptake.
Specifically, propensity score matching is an ideal approach to compare patients who have
received CRC surgery from those who have not. Doing so helps to minimize potential confounding
by indication and make the observed characteristics of the two compared groups similar.
Lastly, we found that urban population is more likely to undergo mCRC surgery. The
finding persisted after accounting for the intestinal obstruction or perforation, which we arguably
assume it distinguishes patients who present with symptomatic and asymptomatic status.
However, in this study, we were unable to account for the impact of surgery volume (both the
hospital volume and the surgeon volume) on the receipt of mCRC surgery between the two
populations.
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Appendices

Appendix A. Rural-Urban Commuting Area Codes Definitions
Category
A

B

C
D
E

F

Definition
1-Urban focused
2-Large Rural City/Town (micropolitan) focused
3-Small Rural Town focused
4-Isolated Small Rural Town focused
1-Urban
2-Large Rural City/Town
3-Small and Isolated Small Rural Town
1-Urban
2-Rural City
1-Urban (≥30% of workers go to Census Bureau-defined urbanized area)
2-Rural City
1-Urban
2-Large Rural City/Town
3-Small Rural Town
4-Isolated Small Rural Town
Adding group that is non-urban and non-large rural
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Appendix B. ICD and CPT Codes
B1. High-risk groups excluded from the study samples
High-Risk Group
ICD Diagnosis
CRC diagnosis
153.0,C183,153.1,C184,153.2,C186,153.3,C187,153.4,C180,153.6,C182,
153.7,C185,153.8,C188,153.9,C189,154.0,C19,154.1,C20,154.8,C218.
Polyps diagnosis
V1272,Z86010
Inflammatory
5551,K5010,5552,K5080,5559,K5090, 5561,K5180,
Bowel Disease
5562,K5120,5563,K5130, 5565,K5150,5566,K5100,
5568,K5180,5569,K5190,5581,K520,5582,K521, 5589,K5289,K529

B2. CRC screening tests
Test type
CPT/ICD Codes
FOBT and FIT 82270, 82272, G0328, 82274
Colonoscopy 4521,4522,4523,4525,44388,44389,44392,44393,44394,44397,45355,
45378,45379,45380,45381,45382,4533,4538,45385,45386,45387.

B3. Diagnosis of CRC
ICD codes
153.0/C183
153.1/C184
153.2/C186
153.3/C187
153.4/C180
153.6/C182
153.7/C185
153.8/C188
153.9/C189
154.0/C19
154.1/C20
154.8/C218

Description
Malignant neoplasm of hepatic flexure
Malignant neoplasm of transverse colon
Malignant neoplasm of descending colon
Malignant neoplasm of sigmoid colon
Malignant neoplasm of cecum
Malignant neoplasm of ascending colon
Malignant neoplasm of splenic flexure
Malignant neoplasm of other specified sites of large intestine
Malignant neoplasm of colon, unspecified site
Malignant neoplasm of rectosigmoid junction
Malignant neoplasm of rectum
Malignant neoplasm of other sites of rectum, rectosigmoid junction,
and anus
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B4. Diagnosis of Metastatic CRC
ICD codes
Description
Secondary and unspecified malignant neoplasm of lymph nodes of
1960/C770
head, face, and neck
Secondary and unspecified malignant neoplasm of intrathoracic lymph
1961/C771
nodes
Secondary and unspecified malignant neoplasm of lymph nodes of
1963/C773
axilla and upper limb
Secondary and unspecified malignant neoplasm of lymph nodes of
1965/C774
inguinal region and lower limb
1970/C7800
Secondary malignant neoplasm of lung
1971/C781
Secondary malignant neoplasm of mediastinum
1972/C782
Secondary malignant neoplasm of pleura
1973/C7839
Secondary malignant neoplasm of other respiratory organs
1974/C784
Secondary malignant neoplasm of small intestine including duodenum
1976/C786
Secondary malignant neoplasm of retroperitoneum and peritoneum
1977/C787
Malignant neoplasm of liver, secondary
1978/C7889
Secondary malignant neoplasm of other digestive organs and spleen
1980/C7900
Secondary malignant neoplasm of kidney
1981/C7911, C7919
Secondary malignant neoplasm of other urinary organs
1982/C792
Secondary malignant neoplasm of skin
1983/C793
Secondary malignant neoplasm of brain and spinal cord
1984/C7932,C7949
Secondary malignant neoplasm of other parts of nervous system
1985/C7951,C7952
Secondary malignant neoplasm of bone and bone marrow
1986/C7960
Secondary malignant neoplasm of ovary
1987/C7970
Secondary malignant neoplasm of adrenal gland
19881/C7981
Secondary malignant neoplasm of breast
19882/C7982
Secondary malignant neoplasm of genital organs
19889/C7989
Secondary malignant neoplasm of other specified sites
1990/C800
Disseminated malignant neoplasm without specification of site

B5. Colonoscopy claims
ICD/CPT codes
4521
4522
4523
4525
44388
44389
44392
44393
44394

Description
Transabdominal large bowel endoscopy
Endoscopy large bowel through stoma
Colonoscopy
Colonoscopy large bowel biopsy
Colonoscopy stoma dx including collection of specimen
Colonoscopy stoma w/biopsy single/multiple
Colonoscopy stoma removal of lesion by hot biopsy forceps
Colonoscopy stoma ablation lesion
Colonoscopy stoma w/ removal of tumor, polyp or other lesions by
snare technique.
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44397
45355
45378
45379
45380
45381
45382
45383
45384
45385
45386
45387

Colonoscopy through stoma; with transendoscopic stent placement
(includes pre-dilation)
Colonoscopy rigid or flexible transabdominal via colotomy single or
multiple
Colonoscopy flexible dx w/collection of specimens when performed
Colonoscopy flexible w/removal of foreign body(s)
Colonoscopy w/biopsy single/multiple
Colonoscopy flexible with directed submucosal injection any
substance
Colonoscopy flexible w/control bleeding any method
Colonoscopy flexible proximal splenic flexure with ablation of lesion
Colonoscopy flexible w/removal lesion by hot biopsy forceps
Colonoscopy flexible w/ removal of tumor polyp lesion snare
technique
Colonoscopy flexible w/transendoscopic balloon dilation
Colonoscopy flexible proximal splenic flexure transendoscopic stent
placement

B6. Use of preventive services
ICD/CPT codes
Description
V700
Routine general medical examination at a health care facility
V708
Other specified general medical examinations
V709
Unspecified general medical examination
V7231
Routine gynecological examination
Encounter for Papanicolaou cervical smear to confirm findings of recent
V7232
normal smear following initial abnormal
Encounter for general adult medical examination without abnormal
Z0000
findings
Z008
Encounter for other general examination
Z0141
Encounter for routine gynecological examination
Encounter for gynecological examination (general) (routine) with
Z01411
abnormal findings
Encounter for gynecological examination (general) (routine) without
Z01419
abnormal findings
Encounter for cervical smear to confirm findings of recent normal
Z0142
smear following initial abnormal smear
99386
Initial preventive medicine new patient 40-64
99396
Periodic preventive medicine established patient 40-64 years
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B7. Colon cancer surgery
ICD/CPT
Description
4571/0dbe0zz,0db
e3zz,0dbe7zz,
Open Multi-Segment Resection Of Large Intestine
0dbe8zz
4572/0dth0zz,
Open Cecectomy Nec
0dth7zz, Dth8zz
4573/0dtf0zz,
0dtf7zz, 0dtf8zz,
Open Right Hemicolectomy Nec
0dtk0zz
4574/0dtl0zz,
Open Transverse Colon Res Nec
0dtl7zz, 0dtl8zz
4575/0dtg0zz,
Open Left Hemicolectmy Nec
0dtg7zz, 0dtg8zz
4576/0dtn0zz,
Open Sigmoidectomy Nec
0dtn7zz, 0dtn8zz
4579
Partial Large Intestine Excision NEC/NOS
4581/0dte4zz
Laparoscopic Total Intra-Abdominal Colectomy
4582/0dte0zz
Open Total Intrabdominal Colectomy
4583/0dte7zz,
Total Abdominal Colectomy Nec/Nos
0dte8zz
1731/0dbe4zz
Laparoscopic Multi- Segment Resection Large Intestine
1732/0dth4zz
Laparoscopic Cecectomy
1733/0dtf4zz
Laparoscopic Right Hemicolectomy
1734/0dtl4zz
Laparoscopic Resection Transverse Colon
1735/0dtg4zz
Laparoscopic Left Hemicolectomy
1736/0dtn4zz
Laparoscopic Sigmoidectomy
1739/0dbe4zz
Laparoscopic Partial Excision Large Intestine Nec
44140
Colectomy Partial W/Anastomosis
44141
Colectomy Partial W/Skin Level Cecostomy/Colostomy
44143
Colectomy Partial W/End Colostomy & Closure Of Distal Segment.
44144
Colectomy Partial W/ Colostomy /Ileostomy & Mucofistula.
44145
Colectomy Partial W/Coloproctostomy
44146
Colectomy Partial W/Coloproctostomy & Colostomy
44147
Colectomy Partial Abdominal & Transanal Approach
44150
Colectomy Total Abdominal W/O Proctectomy W/ Ileostomy
44151
Colectomy Total Abdominal W/O Proctectomy W/Continent Ileostomy
44155
Colectomy Total Abdominal W/Proctectomy W/Ileostomy
44157
Colectomy Total Abdominal W/Proctectomy Ileoanal Anastomosis
Colectomy Total Abdominal W/ Proctectomy Ileoanal Anastomosis &
44158
Reservoir
44160
Colectomy Partial W/Removal Terminal Ileum & Ileocolostomy
44204
Laparoscopic Colectomy Partial W/Anastomosis
44205
Laparoscopic Colectomy Partial W/ Removal Terminal Ileum
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44206
44207
44208
44210
44211
44212

Laparoscopic Colectomy Partial W/End Colostomy & Closure Of Distal
Segment
Laparoscopic Colectomy Partial W/Coloproctostomy Low Pelvic
Anastomosis
Laparoscopic Colectomy Partial W/ Coloproctostomy Low Pelvic
Anastomosis W/Colostomy
Laparoscopic Colectomy Total W/O Proctectomy
W/Ileostomy/Ileoproctostomy
Laparoscopic Colectomy Total Abdominal W/Proctectomy Ileoanal
Anastomosis
Laparoscopic Colectomy Abdominal W/Proctectomy W/Ileostomy

B8. Rectal cancer surgery
ICD/CPT
Description
44145
Colectomy Prtl W/Coloproctostomy.
44146
Colectomy Prtl W/Coloproctostomy & Colostomy.
44147
Colectomy Prtl Abdominal & Transanal Approach.
44155
TPC - Total Proctocolectomy, Ileostomy Includes Stoma.
44156
TPC - Total Proctocolectomy, Continent Ileostomy Includes Stoma.
TPC, IAA - Ileo-Anal Anastomosis, Straight With Or Without Stoma,
44157
Code Stoma Separately When Done.
44158
TPC, IPAA - Ileal Pouch-Anal Anastomosis.
44207
Laps Colectomy Prtl W/Colopxtstmy Lw Anast.
44208
Laps Colectomy Prtl W/Colopxtstmy Lw Anast W/Clst
44211
Laps Colct Ttl Abd W/Prctect Ileoanal Anastomosis
44212
Laparoscopic TPC - Total Proctocolectomy, Includes Stoma
44238
Unlisted Laparoscopy Procedure, Intestine.
45499
Unlisted Laparoscopy Rectum.
45110
Proctectomy , APR, Colostomy Includes Stoma
45111
Prctect Prtl Rescj Rectum Tabdl Appr
45112
Prctect Cmbn Abdominoprnl Pull-Thru Px
45113
Prctect Prtl W/Mucosec Ileoanal Anast Rsvr
Proctectomy, Combined Abdominal And Transsacral Approach With Or
45114
Without Stoma
Proctectomy, Partial, Parasacral (Kraske Or York-Mason Approach)
45116
Anorectal Procedures Transanal Excision
45119
Prctect Cmbn Pull-Thru W/Rsvr W/Ntrstm
45120

Prctect Compl W/Pull-Thru Px & Anastomosis

45121

Proctocolectomy, For Congenital Megacolon, Including Total Colectomy
With Pull-Through (Eg, Swenson, Duhamel, Or Soave) With Or Without
Stoma, Code Stoma Separately When Done

45123
45126

Prctect Prtl W/O Anast Prnl Appr
Pelvic Exenteration For Colorectal Malignancy, With Proctectomy (With
Or Without Colostomy), With Removal Of Bladder And Ureteral
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45160
45170
45171
45172
45190
45395
45999
45397
483
4831
4832, 0d5p0zz,
0d5p3zz,0d5p4zz,
0d5p7zz, 0d5p8zz
4833
4834
4835, 0dbp3zz,
0dbp7zz, 0dbp8zz
4836, 0dbp4zz,
0dbp8zz
4840,0dtp0zz,
0dtp4zz
4841
4842, 0dtp4zz
4843, 0dtp0zz
4849, 0dtp0zz,
0dtp4zz
4850, 0dtp0zz ,
0dtp4zz , 0dtp7zz ,
0dtp8zz, 0d1n0z4
4851, 0dtp4zz,
0d1n0z4
4852, 0dtp0zz,
0d1n0z4
4859, 0dtp7zz,
0dtp8zz, 0d1n0z4
486
4861
4862, 0dtp0zz,
0dtp4zz, 0d1n0z4,
0d1n4z4
4863, 0dtp0zz,
0dtp4zz
4864

Transplantations, And Hysterectomy, Or Cervicectomy, With Or
Without Removal Of Tube(S), With Or Without Removal Of Ovary(S),
Exc Rct Tum Proctotomy Transsac/Transcoccyge
Excision Of Rectal Tumor, Transanal Approach CPT Expanded
Exc Rct Tum Not Incl Muscularis Propria
Exc Rct Tum Incl Muscularis Propria
Destruction Rectal Tumor Transanal Approach
Proctectomy, APR, Colostomy, Laparoscopic Includes Stoma
Unlisted Procedure, Rectum (Open)
Laps Proctectomy Combined Pull-Thru W/Reservoir
Local Excision Or Destruction Of Lesion Or Tissue Of Rectum
Radical Electrocoagulation Of Rectal Lesion Or Tissue
Other Electrocoagulation Of Rectal Lesion Or Tissue

Destruction Of Rectal Lesion Or Tissue By Laser
Destruction Of Rectal Lesion Or Tissue By Cryosurgery
Local Excision Of Rectal Lesion Or Tissue
[Endoscopic] Polypectomy Of Rectum
Pull-Through Resection Of Rectum, Not Otherwise Specified
Soave Submucosal Resection Of Rectum
Laparoscopic Pull-Through Resection Of Rectum
Open Pull-Through Resection Of Rectum
Other Pull-Through Resection Of Rectum

Abdominoperineal Resection Of The Rectum, Not Otherwise Specified
Laparoscopic Abdominoperineal Resection Of The Rectum
Open Abdominoperineal Resection Of The Rectum
Other Abdominoperineal Resection Of The Rectum
Other Resection Of Rectum
Transsacral Rectosigmoidectomy
Anterior Resection Of Rectum With Synchronous Colostomy

Other Anterior Resection Of Rectum
Posterior Resection Of Rectum
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4865

Duhamel Resection Of Rectum

B9. Primary Care Physician Codes
ICD/CPT

Description

001

General practice

011

Internal medicine

008

Family practice

B10. Stoma Codes
ICD/CPT
4610, 0D1H0Z4,0D1H4Z4,0D1H8Z4,0D1K0Z4,
0D1K4Z4,0D1K8Z4,0D1L0Z4,0D1L4Z4,0D1L8Z4,
0D1N0Z4,0D1N4Z4,0D1N8Z4,4620,0D1B0Z4,
0D1B4Z4,0D1B8Z4,4621,0D1B0Z4
,0D1B4Z4,0D1B8Z4,
4611
4613
4620, 0D1B0Z4,0D1B4Z4,0D1B8Z4
V44.2
V44.3
4621
4623
44141
44143
44144
44146
44150
44155

Description
Colostomy NOS

Temporary colostomy
Permanent colostomy
Ileostomy NOS
Ileostomy
colostomy
Temporary ileostomy
Permanent ileostomy NEC
COLECTOMY PRTL W/SKIN LEVEL
CECOST/COLOSTOMY
COLECTOMY PRTL W/END COLOSTOMY &
CLSR DSTL SGMT
COLECTOMY PRTL W/COLOST/ILEOST &
MUCOFISTULA
COLECTOMY PRTL W/COLOPROCTOSTOMY
& COLOSTOMY
COLCT TOT ABDL W/O PRCTECT
W/ILEOST/ILEOPXTS
COLECTOMY TOT ABDL W/PROCTECTOMY
W/ILEOSTOMY
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Appendix C. Sensitivity Analyses
C1. Definitions to Identify CRC Diagnosis

C1.1. Definition#1175
First: Before applying any definition: We identify members 50-64 years old who were continuously
enrolled for each single year. For example, there were 113,333 members who were continuously
enrolled in the year of 2015 (see tables below). For those members, we identify any diagnosis of
CRC according to the year of diagnosis. For instance, there were 390 members (out of the 113,333
members) with any CRC diagnosis in the year 2015, 362 in the year 2014 and so on.

Eligibility Criteria
BCBS members ages 50-64 - Continuously Enrolled January 1, 2015 - December 31, 2015
N = 113333
Any dx of CRC
2012
2013
2014
2015
N
230
269
362
390
Eligibility Criteria
BCBS members ages 50-64 - Continuously Enrolled January 1, 2014 - December 31, 2014
N = 119732
Any dx of CRC
2012
2013
2014
N
259
312
412
Eligibility Criteria
BCBS members ages 50-64 - Continuously Enrolled January 1, 2013 - December 31, 2013
N = 122531
Any dx of CRC
2012
2013
N
307
363
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Eligibility Criteria
BCBS members ages 50-64 - Continuously Enrolled January 1, 2012 - December 31, 2012
N = 115474
Any dx of CRC
2012
N
336

Second: After applying definition#1 (Among cohort with ≥ 1 CRC DX + any surgery related
during the same hospitalization and/or visit).
A total of 241 members 50-64 years old were continuously enrolled for the year 2015 had CRC diagnosis.
Eligibility Criteria
BCBS members ages 50-64 - Continuously Enrolled January 1, 2015 - December 31, 2015
N = 241
Any dx of CRC
2012
2013
2014
2015
N
42
53
72
69
Eligibility Criteria
BCBS members ages 50-64 - Continuously Enrolled January 1, 2014 - December 31, 2014
N = 260
Any dx of CRC
2012
2013
2014
N
49
62
80
Eligibility Criteria
BCBS members ages 50-64 - Continuously Enrolled January 1, 2013 - December 31, 2013
N = 266
Any dx of CRC
2012
2013
N
57
73
Eligibility Criteria
BCBS members ages 50-64 - Continuously Enrolled January 1, 2012 - December 31, 2012
N = 255
Any dx of CRC
2012
N
59
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Third: Variations in timing of CRC DX according to different periods of continuous enrollment in BCBSNE.
Any CRC dx 1st CRC dx Any CRC dx 1st CRC dx Any CRC dx 1st CRC dx Any CRC dx 1st CRC dx
N in 2012
in 2012
in 2013
in 2013
in 2014
in 2014
in 2015
in 2015
Enrolled > 4 months 317
67
67
78
73
89
84
76
69
Enrolled > 6 months

316

67

67

78

73

89

84

76

69

Enrolled > 9 months

312

67

67

78

73

87

82

76

69

Enrolled > 12 months 308

64

64

78

73

87

82

75

68
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Fourth: Variations in period of continuous enrollment by different CRC-free periods (4-12 months)
FOR THOSE ENROLLED > 4 MONTHS
Number of cases with at least 1 CRC dx with no other CRC dx in prior 4 months
N
2012
2013
2014
2015
284
44
72
82
64

FOR THOSE ENROLLED > 6 MONTHS
Number of cases with at least 1 CRC dx with no other CRC dx in prior 6 months
N
2012
2013
2014
2015
267
34
70
78
64

FOR THOSE ENROLLED > 12 MONTHS
Number of cases with at least 1 CRC dx with no other CRC dx in prior 12 months
N
2012
2013
2014
2015
222
0
67
73
62
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C1.2. Definition#2
First: Before applying any definition (see C1.1. above)
Second: After applying definition#2 (Among cohort with ≥2 CRC within 2 months).
Eligibility Criteria
BCBS members ages 50-64 - Continuously Enrolled January 1, 2015 - December 31, 2015
N = 414
Any dx of CRC
2012
2013
2014
2015
N
124
72
107
71
Eligibility Criteria
BCBS members ages 50-64 - Continuously Enrolled January 1, 2014 - December 31, 2014
N = 455
Any dx of CRC
2012
2013
2014
N
141
93
115
Eligibility Criteria
BCBS members ages 50-64 - Continuously Enrolled January 1, 2013 - December 31, 2013
N = 478
Any dx of CRC
2012
2013
N
177
104

Eligibility Criteria
BCBS members ages 50-64 - Continuously Enrolled January 1, 2012 - December 31, 2012
N = 479
Any dx of CRC
2012
N
206
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Third: Variations in timing of CRC DX according to different periods of continuous enrollment in BCBSNE
Any CRC dx 1st CRC dx Any CRC dx 1st CRC dx Any CRC dx 1st CRC dx
N in 2012
in 2012
in 2013
in 2013
in 2014
in 2014
Enrolled >4 months 637
231
231
117
102
141
124
Enrolled >6 months 633
229
229
116
101
141
124
Enrolled >9 months 613
224
224
116
101
137
120
Enrolled >12 months 592
211
211
115
100
134
117

Any CRC dx
in 2015
95
95
94
91

1st CRC dx
in 2015
86
86
85
82
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Fourth: Variations in period of continuous enrollment by different CRC-free periods (4-12 months)
FOR THOSE ENROLLED > 4 MONTHS
Number of cases with at least 1 CRC dx with no other CRC dx in prior 4 months
N
2012
2013
2014
2015
456
95
107
127
83

FOR THOSE ENROLLED > 6 MONTHS
Number of cases with at least 1 CRC dx with no other CRC dx in prior 6 months
N
2012
2013
2014
2015
405
64
103
115
81
FOR THOSE ENROLLED > 12 MONTHS
Number of cases with at least 1 CRC dx with no other CRC dx in prior 12 months
N
2012
2013
2014
2015
316
0
95
106
74
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C1.3. Definition#3
First: Before applying any definition (see C1.1. above)
Second: After applying definition#4 (Among Cohort with At Least 1 Inpatient or at Least 2 Outpatient
Visits with CRC Diagnoses During Study Period).
Eligibility Criteria
BCBS members ages 50-64 - Continuously Enrolled January 1, 2015 - December 31, 2015
N = 514
Any dx of CRC
201
201
201
201
2
3
4
5
N
201
251
332
369
Eligibility Criteria
BCBS members ages 50-64 - Continuously Enrolled January 1, 2014 - December 31, 2014
N = 562
Any dx of CRC
2012
2013
2014
N
226
292
376
Eligibility Criteria
BCBS members ages 50-64 - Continuously Enrolled January 1, 2013 - December 31, 2013
N = 587
Any dx of CRC
2012
2013
N
270
337

Eligibility Criteria
BCBS members ages 50-64 - Continuously Enrolled January 1, 2012 - December 31, 2012
N = 580
Any dx of CRC
201
2
N
296
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Third: Variations in timing of CRC DX according to different periods of continuous enrollment in BCBSNE.
Any CRC dx 1st CRC dx Any CRC dx 1st CRC dx Any CRC dx 1st CRC dx
N in 2012
in 2012
in 2013
in 2013
in 2014
in 2014
Enrolled >4 months 774
333
333
390
130
437
152
Enrolled >6 months 769
330
330
389
129
437
152
Enrolled >9 months 744
323
323
389
129
433
148
Enrolled >12 months 719
310
310
387
128
428
144
Enrolled >18 months 674
289
289
363
123
419
140
Enrolled >24 months 611
259
259
326
111
404
130

Any CRC dx
in 2015
428
428
427
418
403
383

1st CRC dx
in 2015
105
105
104
98
85
76

129

Fourth: Variations in period of continuous enrollment by different CRC-free periods (4-12 months)
FOR THOSE ENROLLED > 4 MONTHS: 774
Number of cases with at least 1 CRC dx with no other CRC dx in prior 4 months
N
2012
2013
2014
2015
500
129
113
128
88
FOR THOSE ENROLLED > 6 MONTHS: 769
Number of cases with at least 1 CRC dx with no other CRC dx in prior 6 months
N
2012
2013
2014
2015
437
83
109
120
85
FOR THOSE ENROLLED > 12 MONTHS: 719
Number of cases with at least 1 CRC dx with no other CRC dx in prior 12 months
N
2012
2013
2014
2015
327
0
99
110
79
FOR THOSE ENROLLED > 18 MONTHS: 674
Number of cases with at least 1 CRC dx with no other CRC dx in prior 18 months
N
2012
2013
2014
2015
262
0
47
105
74
FOR THOSE ENROLLED > 24 MONTHS: 611
Number of cases with at least 1 CRC dx with no other CRC dx in prior 24 months
N
2012
2013
2014
2015
205
0
0
104
66
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C2. The impact of sensitivity and specificity of various definitions on the association between travel time and stage at diagnosis.
Corrected estimates due to
induction
Misclassifications
period
travel (cancerNonScenario time
free)
Se*
Sp**
Metastatic
Metastatic
total
ORcorr†
InORm†† up/down
<17
0
1
1
13
88
101
1
≥17
0
1
1
14
89
103 0.93912
Ref.
<17
0 0.8118
0.9922
15.19
85.81
101
2
≥17
0 0.8118
0.9922
16.41
86.59
103 0.934
0.006
Up
<17
6 0.8398
0.9935
14.81
86.19
101
3
≥17
6 0.8398
0.9935
16.00
87.00
103 0.93472
0.005
Up
<17
6 0.8398
0.97
12.31
88.69
101
4
≥17
6 0.8398
0.97
13.47
89.53
103 0.92249
0.018
Up
<17
6 0.6725
0.9935
18.53
82.47
101
5
≥17
6 0.6725
0.9935
20.02
82.98
103 0.93178
0.008
Up
<17
12 0.8434
0.9938
14.78
86.22
101
6
≥17
12 0.8434
0.9938
15.96
87.04
103 0.935
0.005
Up
<17
18 0.8475
0.9938
14.71
86.29
101
7
≥17
18 0.8475
0.9938
15.88
87.12
103 0.93495
0.004
Up
<17
24 0.8555
0.9939
14.58
86.42
101
8
≥17
24 0.8555
0.9939
15.74
87.26
103 0.935
0.004
Up
<17
30 0.8579
0.994
14.55
86.45
101
9
≥17
30 0.8579
0.994
15.71
87.29
103 0.93517
0.004
Up
<17
36 0.8616
0.994
14.49
86.51
101
10
≥17
36 0.8616
0.994
15.64
87.36
103 0.935
0.004
Up
*Sensitivity,** Specificity, † Corrected odds ratio.†† InORm (Natural log of odds ratio due to misclassification)= Ln(ORobserved/ORcorrected).
The range of sensitivity and specify were derived from Setoguchi et. al.175

Bias
direction

Toward
Toward
Toward
Toward
Toward
Toward
Toward
Toward
Toward
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C3. The Magnitude of Change in Odds Ratio According to Different Travel Times
Time variations
OR
Original
0.996 (0.985,1.008)
1 minute
0.996 (0.985,1.008)
10 minutes
0.997 (0.985,1.009)
20 minutes
0.997 (0.985,1.009)
30 minutes
0.998 (0.986,1.010)

C4. Frequency of Colorectal Cancer Cases Identified According to Different Periods of
Colonoscopy Use
Continuous enrollment period
Total CRC cases
3 months before or 14 days after CRC diagnosis
200
4 months before or 14 days after CRC diagnosis
204
6 months or 14 days after CRC diagnosis
210
12 months or 14 days after CRC diagnosis
258

C5. Identification of Colorectal Cancer Cases According to Periods of Continuous Enrollment
Continuous enrollment period
Total CRC cases
3 months before CRC Diagnosis
453
4 months before CRC Diagnosis
429
6 months before CRC Diagnosis
366
12 months before CRC Diagnosis
279
18 months before CRC Diagnosis
228
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C6. Definitions to Identify Colonoscopy Use

Identifying Colonoscopy Using Definition 1: Continuous
Enrollment of ≥6 months (n=269)

Non-metastatic CRC DX
N= 213

Metastatic CRC
N=19

No surgery anytime
N= 0

With CRC surgery anytime
N= 213

No surgery within 6 months after
CRC DX N= 0

Any time colonoscopy
N= 210

With CRC surgery within 6 months
after CRC DX
N= 213

4 months pre or 2 weeks post
CRC DX N= 198
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Identifying Colonoscopy Using Definition 2: Continuous
Enrollment of ≥6 months (n=735)

Non-metastatic CRC DX
N= 542

Metastatic CRC
N=193

No surgery

With CRC surgery
N= 316

N= 226

No surgery
N= 76

Any time colonoscopy
N= 203

With CRC surgery
N= 240

4 months pre or 2 weeks
post CRC DX
N= 195
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Identifying Colonoscopy Using Definition 3: Continuous
Enrollment of ≥6 months (n=735)

Non-metastatic CRC DX
N= 542

Metastatic CRC
N=193

No surgery anytime
N= 226

With CRC surgery anytime
N= 316

No surgery within 6 months
after CRC DX N= 76

Any time colonoscopy
N= 239

With surgery within 6 months
after CRC DX N= 240

4 months before or 2 weeks
post CRC DX
N= 209
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C7. Definition of CRC Diagnosis by Year of Diagnosis
BCBS members ages 50-64 continuously enrolled between…

N

Definition 1 Definition 2 Definition 3

January 1, 2012 - December 31, 2012

115,474

255

479

580

January 1, 2013 - December 31, 2013

122,531

266

478

587

January 1, 2014 - December 31, 2014

119,732

260

455

562

January 1, 2015 - December 31, 2015

113,333

241

414

514

N: Members who were continuously enrolled during a single year
Definition 1: Among cohort with ≥ 1 CRC + any surgery related during the same hospitalization
and/or visit.
Definition 2: Among cohort with ≥2 CRC diagnosis within 2 months
Definition 3: Among cohort with at least 1 inpatient or at least 2 outpatient visits with CRC
diagnoses during the study period.
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Appendix D. Comparison between the BCBSNE and the State of Nebraska
Population
D. Frequencies and Percentages of BCBSNE and The State of Nebraska Population by Regional
Health Department
Region
BCBSNE members
The State of Nebraska
Panhandle Public Health District
North Central District Health
Department
Northeast Nebraska Public Health
Department
Dakota County Health Department
West Central District Health
Department
Loup Basin Public Health
Department
East Central District Health
Department
Elkhorn Logan Valley Public Health
Department
Three Rivers Public Health
Department
Lincoln/Lancaster County Health
Department
Sarby/Cass Department of Health
and Wellness
Douglas County Health Department
Southwest Nebraska Public Health
Department
Two Rivers Public Health
Department
South Heartland District Health
Department
Central District Health Department
Public Health Solutions District
Health Department
Four Corners Health Department
Southeast District Health
Department
Total

N
25731

%
3.74

N
88403

%
4.85

19938

2.90

46394

2.54

10331
2656

1.50
0.39

31387
21006

1.72
1.15

1584

0.23

39433

2.16

14229

2.07

31140

1.71

21093

3.06

51992

2.85

23461

3.41

57002

3.13

32598

4.74

77705

4.26

122961

17.86

285407

15.65

67846
189848

9.86
27.58

184081
517110

10.10
28.36

18061

2.62

36987

2.03

38224

5.55

94797

5.20

19033
26997

2.77
3.92

46218
75576

2.53
4.14

21768
17086

3.16
2.48

55176
44216

3.03
2.42

14844

2.16

39341

2.16

673445

100.0

1823371

100.0
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